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1. Introduction 
1.1. Multiple Sclerosis 
1.1.1. Relevance and epidemiology 
Multiple Sclerosis (MS) is a chronic degenerative disease of the central nervous system 
(CNS). Up to 2.5 million people are diagnosed with MS worldwide (WHO, 2004). In Germany, 
approximately 120,000 people are affected and the yearly incidence rate is estimated to be 
3.5-5 per 100,000 inhabitants (Compston, 2006; Hein & Hopfenmüller, 2000). 
The typical onset of MS is between the ages of 20 and 40, however, children, teenagers and 
older adults can be affected as well (Bobholz & Gremley, 2011). Overall, women are affected 
more often than men with a ratio of 2-3 to 1 (DeLuca & Nocentini, 2011). Also, MS is more 
prevalent in countries of higher latitude, i.e., countries farther away from the equator 
(Simpson, Blizzard, Otahal, Van der Mei, & Taylor, 2011). 
MS is the most frequent neurological disorder that leads to permanent disabilities in 
younger adults (DGNLL, 2014) and although modern treatment helps to slow down the 
disease progression and to ease many of its symptoms, MS itself can neither be cured nor 
prevented. The economic effects are huge due to the fact that MS-patients have more 
absences from work, retire early, and need expensive treatment (Flachenecker et al., 2005). 
The annual costs add up to an estimate of 33,000 Euro per patient and year in Germany 
(DGNLL, 2014). 
1.1.2. Symptoms and disease course 
There are at least four distinct, clinical courses that are used to describe MS-related disease 
activity (DGNLL, 2014): 
(1) Clinically isolated syndrome (CIS): First manifestation of symptoms that persist for at 
least 24 hours and suggest demyelination. Symptoms can include one or more 
neurological function. About half the patients with CIS convert to a clinical, definite 
MS within two years (D’Alessandro et al., 2013). 
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(2) Relapsing-remitting MS (RRMS): The most frequent course at disease onset. This 
stage is characterized by sudden manifestations of neurological symptoms 
(“relapses”) which are followed by complete or partial recovery over the course of 6-
8 weeks (“remission”). In untreated MS, the average relapse rate is 1.8 per year. The 
relapse rate typically decelerates over the years. 
 
(3) Secondary progressive MS (SPMS): The majority of patients with an initial RRMS (i.e., 
80%) convert to SPMS after an average of 10 years. This course is characterized by 
progressive, neurological worsening independently of relapses, which occur less 
frequent or not at all. 
 
(4) Primary progressive MS (PPMS): This course is prevalent in about 10 to 15% of MS 
patients. It is characterized by progressive, neurological decline, from the disease 
onset, and absence of clear relapses and remissions. To classify patients with 
occasional relapses additional to the progressive decline, the term progressive 
relapsing MS has been introduced. 
Additionally, the concepts of benign MS and malign MS have been introduced to contrast 
patients with a very mild (minor disabilities after 15 and more years) as opposed to a very 
severe disease course (rapid worsening leading to severe disabilities or death soon after 
disease onset) (Correale, Peirano, & Romano, 2012). 
Several different neurological functions can be impaired by MS and therefore the clinical 
manifestation can vary considerably between individuals. Most prevalent are physical 
symptoms such as sensory disturbances in limbs (e.g., paresthesia), distorted vision, and 
motor disturbances (e.g., spasms, ataxia). Other common symptoms include pain, dysarthria, 
dysphagia, and dysautonomia (especially affecting bladder, intestinal, and sexual functions) 
(Bobholz & Gremley, 2011). Patients with MS are also frequently affected by “invisible” 
neuropsychological symptoms (DGNLL, 2014) such as cognitive impairment, disturbed mood 
and affective regulation (i.e., major depression, bipolar disorder, emotional incontinence, 
and euphoria), anxiety, paranoia, apathy/fatigue, and alteration of personality (DeLuca & 
Nocentini, 2011; Hafler et al., 2005; Haussleiter, Brüne, & Juckel, 2009; Siegert & Abernethy, 
2005; Tiemann, Penner, Haupts, Schlegel, & Calabrese, 2009). 
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Disease severity is conventionally measured by using the Expanded Disability Status Scale 
(EDSS) (Kurtzke, 1983). The EDSS is a rating scale that classifies disability as a score between 
0 and 10. Scores of 1 and 1.5 refer to minimal signs in one or more functional systems but no 
disability. Minimal disability in one or two functional systems is classified as 2.0 and 2.5, 
respectively. An EDSS of 3 and higher indicates at least moderate disabilities and is the cut-
off for benign MS. Other milestones are an EDSS of 4 (i.e., not fully ambulatory), 6 (i.e., 
ambulatory only with aid), and 8 (i.e., essentially restricted to a bed or chair). 
The median time to reach an EDSS of 4, 6, and 7 are about 8, 20, and 30 years after disease 
onset, respectively (Vukusic & Confavreux, 2007). Conversion from RRMS to SPMS typically 
occurs between the age of 40 and 44 (Olek, 2005). Although several prognostic factors have 
been identified in epidemiological studies, the results are not consistent and 
recommendations for an accurate individual prognosis are not yet available (Olek, 2005). 
Factors that have been associated with a favorable prognosis include female sex, young age 
at disease onset, winter birth, optic neuritis, and sensory symptoms at onset. In contrast, a 
progressive course, bladder or bowel symptoms at onset, incomplete recovery from the first 
attack, a short interval between the first and second attack, early accumulation of disability, 
motor or cerebellar symptoms at onset may indicate a rather poor prognosis (Langer-Gould 
et al., 2006). Providing an individual prognosis remains to be a challenge. However, 
epidemiological data can be used by patients and clinicians to track the individual disease 
progression relative to reference cohorts (Kister et al., 2013).   
1.1.3. Pathophysiology 
MS is considered an autoimmune or immune-mediated disease in which the immune system 
attacks cells in the central nervous system that causes a cascade of inflammation, 
demyelination and remyelination, oligodendrocyte depletion and astrocytosis, and neuronal 
and axon degeneration (Compston & Coles, 2008). These processes can affect both parts of 
the CNS, i.e., the brain and the spinal cord, and result in damaged white and grey matter 
(Lucchinetti et al., 2011). The characterizing pathology of MS is the accumulation of 
demyelinated plaques that appear as scars and this gave the disease its name (ancient 
Greek: sklērós, “hard”). Especially at later stages, whole brain atrophy becomes another 
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eminent pathology which probably reflects the axonal loss and has the strongest correlation 
with disease progression. 
1.1.4. Treatment 
Although there still is no cure for MS, several treatment options are available that have a 
positive effect on MS-related symptoms and disease progression. In Germany, treatment 
recommendations are based on three different levels of disease activity, i.e., treatment of 
acute relapses, treatment of mild to moderate active MS, and treatment of highly active MS 
(DGNLL, 2014; Qualitätshandbuch MS / NMOSD, 2017). 
Acute relapses are treated using corticosteroids, usually over the course of three to five 
days. If the symptoms associated with the present relapse persist, plasma exchange or 
immuno-adsorption can be applied as second line treatment. 
Patients with CIS, RRMS, or SPMS who recovered from an acute relapse are treated with 
disease modifying drugs. These are immunomodulatory or immunosuppressive substances 
that decrease the risk of conversion from CIS to MS, reduce the rate of future relapses and 
slow down disease progression. For patients with PPMS, no disease modifying therapy has 
been recommended yet, however, a new treatment option was approved by the American 
Food and Drug Administration in 2017 and may become available to German patients soon 
(Montalban et al., 2017). 
The first approved disease modifying drug for MS was interferon beta which was introduced 
in Germany in 1995 and replaced the off-label use of azathioprine as the primary choice for 
MS treatment. In the following years, additional immunomodulatory substances have been 
approved for treatment of mild/moderately active MS (e.g., glatiramer acetate, 2001; 
teriflunomide, 2013; dimethyl fumarate, 2014) (Qualitätshandbuch MS / NMOSD, 2017). 
Because most of these substances require frequent self-injections, but do not have an 
immediate effect, compliance issues are likely. Resolving these is important because clinical 
trials have shown that the early initiation of treatment cannot be made up by treatment in 
later stages (Edan et al., 2014) suggesting an early window of therapeutic opportunity (Cocco 
et al., 2015). A promising approach to improve compliance is based on psychoeducation for 
newly diagnosed patients (Deppe et al., 2012). 
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In case of a highly active MS (i.e., either significant disease activity despite 
immunomodulatory treatment, or severe and rapidly progressing remitting disease course) 
another set of highly effective DMD is indicated (Gold, 2012). The first line treatment 
comprises four selective immunosuppressive drugs (i.e., natalizumab, fingolimod, 
alemtuzumab, and daclizumab) that directly regulate the immune system. On one hand this 
medication has superior effects on disease activity compared to immunomodulatory drugs. 
On the other hand, this is accompanied by an increased risk of serious adverse events. 
The aforementioned treatment is applied to decrease disease activity in general. In contrast, 
symptomatic treatment is necessary to treat the particular neurological dysfunctions that 
each patient experiences individually (DeLuca & Nocentini, 2011). It plays an important role 
for maintaining quality of life. For example, the spasticity can be managed relatively well by 
using medical agents and physiotherapy. In case of cognitive impairment, several 
neurostimulants have been investigated in respect to beneficial effects on cognitive 
performance and provided mixed results (Grzegorski & Losy, 2017). Neuropsychological 
rehabilitation could also have a positive effect on cognitive functioning, however, available 
studies only provide low-level evidence (Rosti-Otajärvi & Hämäläinen, 2014).  
1.2. Cognitive impairment in Multiple Sclerosis 
1.2.1. Relevance 
Cognitive impairment, also referred to as cognitive deficit, cognitive decline or cognitive 
dysfunction is one of the numerous neuropsychological deficits that patients with MS can 
experience (Haussleiter et al., 2009). Cognitive impairment has been systematically 
investigated in MS since the 1980s (Amato, Zipoli, & Portaccio, 2008). Between 43 % and 65 
% of MS patients will suffer from cognitive impairment in the course of their disease with 
deficits typically found in the domains of attention, information-processing speed, executive 
functioning, memory and learning (Chiaravalloti & DeLuca, 2008). Tests of information-
processing speed and visual memory are most frequently affected (Benedict, Cookfair, et al., 
2006). Language and intelligence are usually spared and the level of impairment usually 
stays below that found in dementia (Wegener, Marx, & Zettl, 2013).  
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Cognitive impairment has significant impact on psychosocial functioning (Amato et al., 
1995). For example, employment status, driving safety, coping, symptom management, 
medication adherence, competence and independence in daily activities, and rehabilitation 
potential have all been associated with cognitive impairment (Langdon, 2011; Patti, 2009). 
Consequently, cognitive functioning has been included as an outcome of interest in recent 
clinical trials (Erlanger et al., 2014; Penner et al., 2012). 
Cognitive impairment can be found across all stages of MS, though it seems to be more 
prevalent in the progressive course, especially in SPMS compared to RRMS and CIS (Potagas 
et al., 2008). Even patients with benign MS are commonly affected by cognitive impairment 
which is one reason why the definition of benign MS remains controversial (Amato et al., 
2006; Correale et al., 2012). 
1.2.2. Definition 
For a long time, MS related cognitive impairment has been underestimated by clinicians and 
was primarily regarded as a symptom of later disease stages (DeLuca & Nocentini, 2011; 
Heaton, Nelson, Thompson, Burks, & Franklin, 1985; Hoffmann, Tittgemeyer, & von Cramon, 
2007). In the past years though, a number of studies investigated cognitive functions in early 
stage MS and suggested that cognitive impairment can be present already at this stage 
affecting between 22 % and 54 % of patients (Achiron & Barak, 2003; Amato, Portaccio, 
Goretti, Zipoli, Hakiki, et al., 2010; Jønsson et al., 2006; Schulz, Kopp, Kunkel, & Faiss, 2006; 
Simioni, Ruffieux, Bruggimann, Annoni, & Schluep, 2007).  
However, it has been criticized that many of these and other related studies were discrepant 
in respect to methods and material, hindering the understanding of cognitive impairment in 
MS (Achiron & Barak, 2006; Hoffmann et al., 2007). One of these discrepancies was lacking 
consent on the definition of cognitive impairment in terms of reliable cut-offs and statistical 
procedures. The comparability of many cognitive studies is already limited by the fact that 
different test batteries were used. An inconsistent classification of cognitive impairment 
would reduce comparability across different studies even more. Additionally, classification 
based on rather liberal criteria could overestimate the prevalence rates, especially in early 
disease stages. 
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Therefore, to promote a more homogenized use of cut-off criteria, the first study of this 
thesis was conducted to systematically review the use of classification criteria in the 
literature, to evaluate possible correlations between their usage and sample characteristics 
(such as disease duration), and to compare classifications resulting from different criteria in 
a new sample of MS patients. 
1.2.3. Assessment batteries 
Cognitive assessment in clinical practice is a trade-off between validity, practicality, time, 
and appropriateness for the patient. Depending on its purpose, the neuropsychological 
examination may only comprise of a short screening or a comprehensive test battery lasting 
2 hours and more and covering a broad range of cognitive functions. For neurological 
diseases with a circumscribed deficit profile such as MS, validated, disease-specific 
screenings and test batteries are available that include sensitive tests for impairment in 
domains typically affected by the disease. These batteries can be used to efficiently detect, 
quantify and monitor the magnitude of cognitive impairment and may also guide the test 
selection for a more elaborate assessment in context of descriptive neuropsychological 
questions (Lezak, Howieson, Bigler, & Tranel, 2012). 
In MS, tests of information-processing speed and working memory are recommended to 
screen for cognitive impairment (Rocca et al., 2015). Tests such as the Mini-mental state 
examination that are commonly used to screen for cognitive deficits in other patient groups, 
do not have sufficient sensitivity for the cognitive deficits related to MS (Aupperle, Beatty, 
Shelton, & Gontkovsky, 2002; Beatty, Goodkin, Hertsgaard, & Monson, 1990; Engel, Greim, 
& Zettl, 2007). The same holds true for self-report measures (Benedict et al., 2004). In past 
years, the symbol digit modalities test (SDMT) has become a standard screening test in MS 
additionally to the paced auditory serial addition test (PASAT) (Parmenter & Weinstock-
Guttman, 2007).  
A more detailed screening for MS-related cognitive impairment can be accomplished by 
using the brief repeatable battery of neuropsychological tests (BRB-N) (Rao, Leo, Bernardin, 
& Unverzagt, 1991) which is one of the most frequently used test batteries for MS patients. 
With a duration of 20 minutes, it is very time efficient. This battery assesses information-
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processing speed (SDMT, PASAT), verbal memory (selective reminding test), visual memory 
(10/36 spatial recall test), and verbal fluency (word list generation). 
The minimal assessment of cognitive function in MS (MACFIMS) is the most comprehensive 
standardized test battery for MS (Benedict et al., 2002). It lasts approximately 90 minutes 
and provides additional information on spatial processing and executive functioning. 
However, the examiner needs to be experienced or well trained in applying these tests. 
Therefore, a recent attempt by an international committee of experts was made to establish 
a very brief, easy accessible and easy to administer test battery to assess MS patients 
worldwide, even in small centers with staff members that may not have been trained in 
neuropsychology. The proposed, brief international assessment of cognition for MS 
(BICAMS) (Langdon et al., 2012) comprises the SDMT and the learning trials of two popular 
memory test: the California verbal learning test (CVLT) and the brief visuospatial memory 
test (BVMT). BICAMS has been validated since its publication in different languages and 
countries (Smerbeck et al., 2017) and in respect to a variety of external factors (e.g., Beier et 
al., 2017; Goverover, Chiaravalloti, & DeLuca, 2016). 
The aforementioned assessment batteries implemented traditional cognitive tests which 
have been constructed on a very similar theoretical foundation base (Lezak et al., 2012). In 
essence, cognitive functioning is separated into distinct domains or classes that are assessed 
by applying specific test paradigms. Key domains are attention (including concentration, 
information-processing speed, working memory), visuospatial skills, memory, language, 
executive functioning, and intelligence (concept formation, reasoning) (Bobholz & Gremley, 
2011; Strauss, Sherman, & Spreen, 2006). These are further divided into subdomains, e.g., 
verbal memory versus visual memory, or selective versus divided attention. On one hand 
these theoretical distinctions have “proven useful in psychological assessment generally and 
in neuropsychological assessment particularly” (Lezak et al., 2012, p. 25). On the other hand, 
this traditional framework is increasingly challenged by the growing body of knowledge in 
cognitive neuroscience. Thus, according to Lezak and colleagues, clinical neuropsychologists 
are well aware of the more sophisticated conceptualizations of cognitive functions in the 
experimental literature and anticipate the transfer into practice, i.e., the development of 
novel, neuro-scientific informed tests of specific cognitive functions. 
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The parametric assessment of visual processing capacity based on the theory of visual 
attention (TVA) can be considered a novel test (see chapter 1.3). Therefore, the aim of this 
thesis’s third study was to apply TVA-based testing to MS patients at different disease stages 
and compare the resulting pattern with performance in traditional cognitive tests. 
1.2.4. Memory functioning 
Memory functioning can be impaired in up to 65% of patients with MS (Rao, Grafman, 
DiGiulio, Mittenberg, & Et Al, 1993) and might already be present in the first years of the 
disease (Sicotte et al., 2008). Most commonly affected are episodic and explicit memory, 
whereas semantic, implicit, and autobiographical memory remains mostly preserved 
(Prakash, Snook, Lewis, Motl, & Kramer, 2008). Memory deficits are evident in tests of verbal 
as well as visual memory and the primary core deficit has been attributed to an impaired 
acquisition (Deluca, Leavitt, Chiaravalloti, & Wylie, 2013; Lafosse, Mitchell, Corboy, & Filley, 
2013), although retrieval and storage processes can be disrupted by MS as well (Thornton & 
Raz, 1997). In respect to verbal memory, three distinct patterns have been identified, i.e., 
having either normal functioning, mild to moderate impairment, or severe amnesia-like 
deficits (Beatty et al., 1996). 
The exact neurophysiologic processes causing memory impairment in MS are still unclear. 
However, results from neuroimaging studies are helping to understand the underlying 
mechanisms. These studies have shown that measures of global cerebral damage (such as 
brain atrophy) and the amount of white matter lesions, as well as measures of localized 
damage in strategic areas (such as the hippocampus) are correlated with memory 
impairment (Rocca et al., 2015). Findings from functional MRI studies suggest an additional 
modulating role of functional reorganization in early disease stages which might allow an 
adaptive compensation of structural damage in the memory network by increased functional 
activation (Hulst et al., 2015). Lately, differential contributions of multiple imaging measures 
to cognitive impairment have been evaluated by using multivariate designs. These studies 
confirmed that different global and focal parameters are correlated with different cognitive 
deficits in parallel and that deep grey matter nuclei have the highest predictive value for 
global deficits (Daams et al., 2015; Damjanovic et al., 2017; Debernard et al., 2015; Pinter et 
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al., 2015). However, despite these recent findings, there are still inconsistencies in respect to 
the presence of memory impairment in early disease stages (e.g., Pardini et al., 2014; Sicotte 
et al., 2008) and the role of hippocampal atrophy (e.g., Anderson et al., 2010; Sicotte et al., 
2008). One reason for these might be related to different neuropsychological assessment 
strategies. For example several different memory tests have been used in previous studies 
and information-processing speed as a potential mediator of memory impairment has not 
been considered (Lafosse et al., 2013; Tam & Schmitter-Edgecombe, 2013). 
Thus, the second study of this thesis utilized a multivariate design to evaluate the 
contribution of structural MRI parameters to memory impairment in MS and in addition, 
accounted for methodological details regarding memory assessment. 
1.3. TVA-based assessment of visual processing capacity 
Claus Bundesen’s theory of visual attention (TVA) (Bundesen, 1990) is an influential 
perspective on selective attention. In contrast to other theories, attention is not understood 
as a mental spotlight that serially processes visual information, but as a parallel processing 
race between all information in the visual field (Habekost, Petersen, & Vangkilde, 2014). 
Additionally, TVA is a combined theory of selection and recognition, i.e., the selection of a 
visual object and its transfer into the visual short-term memory (VSMT) are modeled as a 
unified mechanism (Kyllingsbaek, 2006). The details of the postulated processing race are 
specified by a set of mathematical equations (Habekost & Rostrup, 2007) which can be used 
to develop TVA-based assessment tests of visual processing capacity (Foerster, Poth, Behler, 
Botsch, & Schneider, 2016; Kyllingsbaek, 2006).  
1.3.1. Theory of Visual Attention 
According to TVA, the brain processes visual information in a two-stage process which can 
be mathematically formulated (Bundesen, 1990; Bundesen, Habekost, & Kyllingsbaek, 2005; 
Kyllingsbaek, 2006). In a first stage, all visual objects in the visual field are filtered. For this 
purpose different basic features of each object (e.g., a certain color or shape) are matched 
with representations in the visual long-term memory and according to this match are then 
given a sensory evidence value. This is happening for all objects in parallel and initially 
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unselective (in the later descriptions of TVA also referred to as the “first wave”). Thereafter, 
an attentional weight is determined for each object based on the product of sensorial 
evidence and pertinence (i.e., how relevant a feature is for an individual’s perception at this 
moment) for every particular feature. Only after this filtering, in a second, selective stage - 
called pigeonholing – the processing capacity of the visual system is distributed across visual 
objects depending on (1) their attentional weights, (2) the perception bias for object 
categories (e.g., identifying letters), and (3) sensory evidence for the object belonging to 
each of these categories. Thus, the processing speed, i.e., the speed at which a visual object 
is encoded into the visual short-term memory (VSTM) is determined by sensory evidence, 
pertinence, and perception bias. Objects with high processing speed have a higher chance to 
be encoded into VSTM. One object after the other is transferred into VSTM until it is full 
(capacity is typically around 4) and processing is terminated. 
Put differently, visual processing can be considered a race between visual objects for 
reaching VSTM in time. This race is constrained by the total amount of processing speed and 
the maximum capacity of VSTM in a person and affected by top-down (e.g., expectations in 
respect to the visual input; individual long-term memory representations) and bottom-up 
(sensory evidence of each object, number of relevant categories) factors. For this reason, 
TVA is considered to be strongly related to the biased-competition model of visual attention 
(Bublak et al., 2011; Desimone & Duncan, 1995). 
In 2005, a neural interpretation of TVA was introduced to demonstrate that the proposed 
model of visual processing is in accordance with several neurophysiological findings in the 
central nervous system (Bundesen et al., 2005). Essentially, the authors suggest that from a 
single cell perspective, filtering alters the number of cortical neurons in which an object is 
represented, whereas pigeonholing alters the firing rate of cortical neurons for a particular 
feature. From a structural perspective, the authors propose that visual processing is 
distributed across the lateral geniculate nucleus, striate and extrastriate cortical areas, 
pulvinar nucleus of the thalamus, and the thalamic reticular nucleus as a feed-forward loop 
(Bundesen, Habekost, & Kyllingsbæk, 2011). 
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1.3.2. Assessment paradigm 
The equations provided by TVA can be used to assess the visual processing capacity of a 
person from performance in two simple tasks. In these, subjects are briefly presented letter 
arrays and asked to either report all letters (“whole report”) or only letters of a certain type 
which are typically letters of a predefined color (“partial report”) (Shibuya & Bundesen, 
1988; Sperling, 1960). TVA-based testing usually applies one of these tasks with variable 
exposure durations of the letter array as the independent variable (typically between 10 and 
200 milliseconds) and the number of correctly reported letters as the dependent variable. 
The number of presented letters is usually kept constant but their placement on the screen 
is altered randomly. 
The number of correctly reported letters is regarded as an outcome measure of how many 
visual objects were transferred into VSTM as “winners of the race”. In accordance with TVA, 
this number rises with prolongation of exposure duration and the extent to which it does, 
reflects the total processing rate of a persons’ visual system. Additionally, the increase of 
recognized letters ceases at some point which, according to TVA, is determined by the 
capacity limit of a subjects’ VSTM. 
The relation between exposure duration t and reported letters can be modeled for each 
person as an exponential growth function f(t) (Figure 1). From this function the main TVA-
based parameters of visual processing can be derived (Habekost, 2015; Kyllingsbaek, 2006): 
(1) The perceptual threshold t0 is determined by the curves’ origin (f (t) = 0) and represents 
the minimum exposure duration required for the visual system to transfer any meaningful 
object into VSTM. (2) The processing rate C is determined by the curves’ slope at its origin 
and represents the number of visual objects that can be processed per second. (3) The VSTM 
capacity K is determined by the curves asymptote. These parameters can be estimated from 
data acquired in the whole report. From performance difference between unmasked and 
masked trials (see below) iconic memory buffering (μ) can be estimated reflecting the 
additional time a visual percept is available for processing due to visual persistence. 
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Figure 1. Illustration of TVA-based modelling of visual processing capacity.  
A subjects’ performance in the whole report task is used to model an exponential growth function f(t) that relates the mean 
number of correctly reported letters to length of exposure duration. The resulting curve is characterized by three 
parameters reflecting visual processing capacity: The slope at the curve’s origin determines the processing rate C, the 
asymptote determines visual short-term-memory storage capacity (K); the origin determines the perceptual threshold (t0).  
 
Two standard paradigms for TVA-based assessment of visual processing capacity are in use 
(Figure 2). The first one was introduced by Duncan et al. (1999), the second one by Vangkilde 
et al. (2011). In the version of Duncan et al., five letters are displayed in a vertical column 
either to the left or right of a fixation cross. Exposure times are individually adapted and half 
the trials are masked. In the partial report one or two letters of different color (targets or 
distracters) are shown at four possible locations around fixation. The version of Vangkilde et 
al., also called CombiTVA, is a combination of whole and partial report trials. Up to six letters 
are displayed in a circle around the fixation cross and are always post-masked. Furthermore, 
the set of exposure durations is fixed, i.e., the letters are presented to each subject at the 
same exposure durations ranging between 10ms and 200ms. The most recent development 
was a modified version of the CombiTVA whole report for a virtual reality device that could 
simplify a feasible and reliable TVA-based assessment (Foerster et al., 2016). 
The mathematical estimation of the TVA-based parameters from a set of behavioral data can 
be performed by using a program package provided by Kyllingsbaek (2006). It allows 
specifying different models to whole or partial report paradigms as well as subsequent 
parameter estimation. 
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Figure 2. Two standard paradigms for TVA-based assessment of visual processing capacity. 
The whole report version devised by Duncan et al. (1999) and the one devised by Vangkilde et al. (2011) are illustrated. 
Both versions differ in respect to stimuli display (quantity, size, and layout of the letters), exposure duration (fixed vs. 
individually adapted) and masking (unmasked trials included or not). 
 
1.3.3. TVA-based assessment in clinical samples 
TVA-based assessment has several qualities that makes it valuable for the evaluation of 
clinical samples (Habekost, 2015). Firstly, it has a profound theoretical grounding and 
cognitive specificity. Secondly, it assesses visual processing independently of reaction time 
and motor response. Thirdly, the whole and partial report tasks are easy to understand and 
executed. Hence, it comes to no surprise, that TVA-based assessment has been used in over 
30 clinical studies. Up to now, patients suffering from neglect, thalamic stroke, parietal 
stroke, frontal stroke, simultanagnosia, alexia, dyslexia, Huntington’s disease, mild cognitive 
impairment, Alzheimer’s disease, attention deficit hyperactivity disorder, spina bifida, and 
preterm birth have been systematically evaluated by using TVA-based assessment 
(Habekost, 2015). Additionally, results from a first investigation of TVA-based visual 
processing capacity in a small heterogeneous sample of RRMS patients have been recently 
reported (Kluckow, Rehbein, Schwab, Witte, & Bublak, 2016). 
Upon reviewing these former studies, Habekost (2015) concluded that TVA-based 
assessment can be used to acquire reliable and specific visual processing deficit profiles. Its 
cognitive specificity can help to better understand and elaborate attentional deficits 
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resulting from focal or more generalized brain damage. Additionally, TVA-based testing can 
pick up on very subtle visual processing deficits in otherwise cognitively, well-functioning 
individuals (Finke et al., 2015). Kluckow et al. (2016) demonstrated that significant 
alterations of TVA-based parameters are evident in MS patients who are still relatively high-
functioning. 
Therefore, assessing the TVA-based profile of visual processing capacity in larger, more 
homogenous groups of MS patients could help to disentangle its most common cognitive 
deficit, i.e. slowed information-processing speed and moreover, evaluate how sensitive it is 
for visual processing deficits in patients with a very early MS or with still well-preserved 
cognitive functioning. 
1.3.4. Correlation with cognitive functioning 
A systematic comparison between TVA-based parameters of visual processing and cognitive 
functioning as assessed by a broad neuropsychological assessment battery in one clinical 
sample has not been reported yet. However, cognitive functioning in selected cognitive 
domains has been compared to visual processing capacity in two clinical studies. Bublak et 
al. (2011) applied the Mini-Mental State Examination (MMSE) and the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) test battery in a study of elderly 
patients with mild cognitive impairment or probable Alzheimer’s disease. Their data showed 
that the total scores of the MMSE and CERAD were moderately correlated with the TVA-
based processing rate C and weakly with the VSTM storage capacity K. In contrast, they 
found no correlations with the perceptual threshold t0. Kluckow et al. (2016) found a 
significant correlation between processing rate C and an objective measure of fatigue 
derived from performance in the paced auditory serial addition test which is a non-visual 
test sensitive to information-processing speed and working memory deficits ins MS. 
More detailed comparisons between TVA-based assessment and standard cognitive test 
performance were reported by studies of healthy subjects. In their validity study of TVA-
based assessment, Finke et al. (2005) applied standard tests of psychomotor speed 
(alertness, i.e., responsiveness to a simple visual stimulus), spatial distribution of attention 
(visual scanning, i.e., time to detect a target stimulus in the visual field), top-down control 
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(stroop test), working memory capacity (visual memory span subtest from the revised 
Wechsler memory scale), and crystallized intelligence (vocabulary test). They found weak to 
moderate correlations between TVA-based parameters and congruent traditional tests, e.g., 
the TVA-based processing rate C was found to be correlated with psychomotor speed (r = -
.33), VSTM storage capacity K with working memory (r = .29), and the efficiency of top-
down-control α with top-down control (r = .38). In another large-scale study of 325 healthy 
adults, several conventional tests were applied to derive an index of higher order cognitive 
functioning (i.e., California Verbal Learning Test II, a stroop adaption, an experimental letter 
discrimination test) and processing speed (i.e., Digit-symbol substitution test) (Espeseth, 
Vangkilde, Petersen, Dyrholm, & Westlye, 2014). A pattern of weak correlations between 
both indices and t0, C, K, and α were found. However, in a subgroup of elderly an amplified 
correlation with t0 was reported, whereas in people below the age of 50, C and K were the 
predominant correlates. The authors of the study speculated that elevations of the 
perceptual threshold could indirectly explain age-related cognitive decline that is related to 
slowing processing speed. 
These studies show that TVA-based assessment is valid in respect to assessing intact and 
impaired cognitive functioning but not redundant. Moreover, they suggest that the 
correlation pattern changes with the beginning of cognitive decline and this change could be 
differential depending on the factors causing it. Thus, analyzing correlations between TVA-
based visual processing capacity parameters and performance in conventional 
neuropsychological tests could help to understand whether cognitive impairment in MS is 
comparable to cognitive decline associated with Alzheimer’s disease or rather with decline 
associated with age-related factors. 
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1.4. Aim and objectives 
The aim of this thesis was to evaluate established and novel neuropsychological assessment 
strategies for cognitive impairment in MS.  
It was shown in chapter 1.2 that established assessment strategies for cognitive impairment 
in MS have varied in respect to the utilized tests and applied criteria for impairment 
classification which makes it hard to compare the outcomes between different studies. 
Therefore the objective of the first study was to review classification criteria for cognitive 
impairment and compare their outcomes in patients with early and late MS (Fischer et al., 
2014). 
In chapter 1.2.4 it was shown that several conflicting findings exist in respect to the presence 
of memory impairment at different stages of MS and its correlation with hippocampal 
atrophy which might be related to different memory assessment strategies. Thus, the 
objective of the second study was to investigate memory impairment and structural 
magnetic resonance imaging correlates in homogenous groups of early and late MS, 
controlling for a potential information-processing speed deficit, and utilizing multiple 
memory test paradigms (Köhler et al., 2017). 
In chapter 1.2.3 it was argued that established neuropsychological assessment strategies 
utilize tests that, although proven useful, are increasingly challenged in respect to their 
theoretical foundation by insights from modern cognitive neuroscience. Thus, in chapter 1.3 
an alternative, novel assessment strategy based on a theory of visual attention was 
introduced that has been successfully applied to patients with a range of neurological and 
psychiatric conditions. Therefore, the objective of the third study was to assess TVA-based 
visual processing capacity at different stages of MS and its relationship with cognitive 
functioning determined by conventional neuropsychological tests. 
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2. Study one: How reliable is the classification of cognitive 
impairment across different criteria in early and late 
stages of multiple sclerosis? 
2.1. Introduction 
Cognitive impairment (CI), also referred to as cognitive dysfunction, cognitive deficit, and 
cognitive disorder, is a common symptom of multiple sclerosis (MS) (Langdon, 2011). It has 
relevance for many aspects of quality of life, such as maintaining employment, daily-living 
activities, social life, ability to drive, and benefits from in-patient rehabilitation (Patti, 2009). 
Complex attention, information processing speed, verbal and visual-spatial memory, and 
executive functions are frequently impaired in MS, whereas intelligence, language, semantic 
memory and attention span are widely preserved. 
The first signs of CI can already be found at the time of MS onset (Achiron & Barak, 2003; 
Glanz et al., 2007; Potagas et al., 2008; Schulz et al., 2006; Zivadinov, De Masi, et al., 2001). 
In later disease stages, CI seems to progress in terms of prevalence and severity (Glanz, 
Healy, Hviid, Chitnis, & Weiner, 2012). The reported prevalence of CI in MS ranges highly, 
between 40% and 80%. What is the reason for such a large variance?  
Two factors that potentially influence prevalence rates are sample composition and 
neuropsychological assessment (Benedict, 2009). Advanced age, progressive disease course, 
later disease stage, higher physical disability, fatigue, and depression are sample 
characteristics that tend to be associated with CI (Patti, 2009). Psychometrically, the 
classification of CI is based on the comparison of an individual test result to the mean of a 
normative sample. Commonly, performance below one, one-and-a-half, or two standard 
deviations (SD) of the normative mean is used as cut-off for impairment classification. By 
definition, lower cut-offs (e.g., 1 SD) result in higher prevalence rates of CI than conservative 
cut-offs (e.g., 2 SD).  
In neuropsychological practice however, it is common to use a battery of tests instead of a 
single test. This also affects the prevalence rates of CI, because the likelihood of irrelevant 
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impaired results rises with an increasing number of obtained scores (Schretlen, Testa, 
Winicki, Pearlson, & Gordon, 2008). Thus, the outcome of CI is highly influenced by the 
utilized cut-off and the number of tests (Binder, Iverson, & Brooks, 2009).  
In MS, research on cognitive functions focused on finding sensitive and brief test batteries 
for CI in MS (Langdon et al., 2012), but hardly addressed the issue of classification criteria 
(Hoffmann et al., 2007). Many studies used standard test batteries like the brief repeatable 
battery of neuropsychological tests (BRB-N) and defined CI as performance below the fifth 
percentile on about 20% of test parameters or tests (Benedict, 2009). However, more liberal 
(Achiron & Barak, 2003; Deloire et al., 2006; Feuillet et al., 2007) or conservative criteria 
(Hulst et al., 2013), as well as non-standardised test batteries have also been used. 
Furthermore, some authors defined CI by employing composite indices or domain specific 
criteria (Camp, Stevenson, & Thompson, 1999; Khalil et al., 2011; Smestad, Sandvik, Landrø, 
& Celius, 2010).  
To our knowledge, there is no study that compared these different classification strategies. 
Thus, it remains unclear when to utilize which strategy and if different strategies lead to 
comparable outcomes. For the first time, a review of common classification strategies for CI 
in MS is provided and their outcomes are compared. Moreover, we evaluate their diagnostic 
validity in the cognitive assessment of groups in early and late disease stages as compared to 
matched controls. The major goal is to promote a more homogenized use of classification 
strategies that allows better comparability of future studies on cognitive impairment in MS. 
2.2. Methods 
2.2.1. Review 
Literature search 
Reference lists of recent reviews (Achiron & Barak, 2006; Amato et al., 2008; Chiaravalloti & 
DeLuca, 2008; Ferreira, 2010; Hoffmann et al., 2007; Langdon, 2011; Prakash et al., 2008) 
and the online database MEDLINE were searched for original articles on cognitive 
impairment in MS. Search terms were combinations of “multiple sclerosis”, “cognitive 
impairment”, “classification” “composite” and “index”. 
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Selection criteria 
Articles were included if they met the following criteria: (1) published between 1999 and 
2013 in the English language, (2) classification of cognitive impairment, (3) classification 
based on test batteries that comprised a minimum of 5 neuropsychological test parameters 
testing at least 2 cognitive domains. Articles were excluded if the classification criterion was 
not specified or unclear (e.g., number of relevant test parameters not provided). 
Data extraction 
The following data were extracted: name of test battery, number of cognitive parameters 
the classification is based on, critical number of abnormal parameters, SD cut-off, sample 
characteristics (n, disease course, age, disease duration, percentage of impaired patients). 
When possible the criteria were classified with respect to their stringency (liberal, fair, or 
conservative). This was based on false positive rates, i.e., on how many parameters healthy 
people fail on a cut-off of 1, 1.5, and 2 SD (Schretlen et al., 2008). For example, assuming 
that 32% of the parameters in a test battery fall 1 SD below the normative mean in 84 % of 
healthy controls, we considered criteria that define CI as performance below 1 SD on 32 % ± 
6.4 % of test parameters as fair, on less than 25.6 % as liberal, and on more than 38.4% as 
conservative. The respective figures were 17 ± 3.4 % for the 1.5 SD / 5th percentile cut-off, 
and 7.5 ± 1.5% for the 2 SD cut-off. Additionally, a continuous measure of stringency (y) was 
computed by dividing the utilized rate of abnormal parameters (x = critical number of 
abnormal parameters / total number of relevant parameters) from the aforementioned false 
positive rates (i.e., y1SD= x / 32; y1.5SD= x / 17; y2SD= x / 7.5). Higher y represent more stringent 
criteria. 
Statistical analysis 
One-way ANOVAs with Tukey post-hoc tests were performed to determine differences in CI 
and disease duration. Correlations between the continuous measure of stringency, disease 
duration and CI were analysed using the nonparametric Spearman’s rank correlation 
coefficient. 
2.2.2. New data 
  
Page | 23  
Subjects 
Seventy-seven patients with a first clinical demyelinating event related to MS or a deﬁnite 
MS diagnosis according to the criteria of McDonald (Polman et al., 2005) were recruited 
from five multiple sclerosis centres (Table 1). The sample was divided into two groups aged 
between 18 and 55 years, one group having a disease duration less than 2 years from the 
first clinical event (early MS) and the other group with a disease duration longer than 12 
years (late MS). A significant difference in the prevalence of CI can be expected between 
these groups (Amato, Ponziani, Siracusa, & Sorbi, 2001). The two groups were matched with 
respect to age at disease onset (+/- three years), gender and educational level (years of 
education). That means one patient with early MS was matched with two late MS patients. 
The late MS group was twice as large as the early MS group because their data was going to 
be used in another study focusing on MRI correlates of late cognitive impairment. Exclusion 
criteria were a relapse or corticosteroid treatment 4 weeks prior to neuropsychological 
assessment, visual impairment (>0.2), severe fatigue and depression, alcohol abuse, 
pregnancy, and other relevant serious neurological and internal medical diseases as well as 
exclusion criteria for MRI. Depression and fatigue were evaluated with the German version 
of the Center for Epidemiological Studies Depression Scale (Hautzinger & Bailer, 1993) and 
the “Wuerzburger Fatigue Inventory for MS” (Flachenecker et al., 2006). Scores of 39 or 
more and 52 or more were considered indicative of severe depression and fatigue 
respectively. 
Additionally, a group of demographically matched healthy control subjects were recruited. 
Controls also needed to be free of any neurological and psychiatric conditions, as well as 
other medical conditions associated with cognitive impairment. All subjects provided their 
informed consent to participate in the study. The study was approved by the local Ethical 
Committees. Patients, as well as controls, received financial compensation for their travel 
expenses. 
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Table 1. Clinical and demographic variables 
 
group p1 
 
early MS 
(a) 
late MS 
(b) 
controls 
for  
early MS 
(c) 
controls  
for 
late MS 
(d) 
a-b a-c b-d 
N 25 52 25 50 N/A N/A N/A 
Gender (m/f) 8/17 16/36 8/17 14/36 1.000 1.000 0.830 
Age (mean±SD years) 29.2±6.7 45.3±7.8 28.6±7.3 44.4±7.7 0.001 0.734 0.591 
Age at disease onset 
(mean±SD years) 
28.2 (7.0) 28.7 (7.1)   0.78 N/A N/A 
Disease duration 
(mean±SD years) 
1.0±0.8 16.5±5.2   0.001 N/A N/A 
Number of relapses 
past year (mean±SD) 
1.5±1.9 0.3±0.7   0.000 N/A N/A 
Multifocal 
involvement at 
onset2 
24.0% 23.0%   1.000 N/A N/A 
EDSS3 (mean±SD) 2.0±1.4 3.6±2.0   0.001 N/A N/A 
Using MS medication 96.0% 88.5%   0.257 N/A N/A 
Education ≥12y 36.0% 28.8% 36.0% 26.0% 0.603 1.000 0.830 
Depression (CES-D) 
(mean±SD) 
12.8±9.7 13.0±9.2 7.4±4.7 8.8±8.2 0.91 0.017 0.017 
Fatigue (Weimus) 
(mean±SD) 
19.6±16.3 26.6±14.5 6.9±8.3 7.8±10.4 0.06 0.001 0.000 
1: p-values of independent samples t-test, U-test (relapses past year), Fisher's exact test (gender, using MS medication, multifocal 
involvement) 
2: more than one sign or symptom related to MS, e.g., optic neuritis accompanied by muscle weakness 
3: EDSS: Expanded Disability Status Scale 
 
Neuropsychological Assessment 
Trained psychologists administered an extensive neuropsychological test battery including 
common tests for attention, memory, and executive function in a single 2-hour session. 
Responsiveness (alertness), divided attention, and mental flexibility were assessed by using 
the Computerized Test Battery of Attention (TAP) (Zimmermann & Fimm, 2011). Verbal 
memory was assessed by the German version of the Rey Auditory Verbal Learning Test 
(AVLT) (Helmstaedter, Lendt, & Lux, 2001) and by the short form of the Verbal Learning Test 
(VLT) (Sturm & Willmes, 1999). Visuospatial ability and incidental memory were assessed by 
the Rey-Osterrieth Complex Figure Test (ROCF) using the Taylor Scoring System (Strauss et 
al., 2006), while visual learning and memory were measured by the short version of the 
“Diagnosticum fuer Cerebralschaedigung” (Wolfram, Neumann, & Wieczorek, 1989). 
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Furthermore, the short form of the Nonverbal Learning Test (NVLT) (Sturm & Willmes, 1999) 
was used to assess continuous visual recognition learning. Tests were performed in the 
following fixed order: AVLT (learning), ROCF (copy), alertness, divided attention, flexibility, 
AVLT (recall, recognition), ROCF (recall), DCS, VLT, and NVLT. 
Individual raw scores were converted to standard T-scores based on age- and gender-
matched normative data from the corresponding test manuals. Normative data of the 
attention tests and the VLT and NVLT were also matched in respect to education. Each Rey-
Figure was scored independently by two psychologists which a third psychologist used to 
conduct the final scoring. Fifteen parameters were considered relevant for impairment 
classification: Alertness: Median reaction time with (1) and without auditory cue (2); Divided 
Attention: Median reaction time auditory (3) and visual (4), errors (5), omissions (6); 
Flexibility: Index of overall performance (7); AVLT: Recall trial 1-5 (8), difference trial 5 and 
delayed free recall (9), recognition (10); ROCF: Delayed recall (11); DCS: Memory index first 
trial (12), learning index (13); VLT: Difference of true and false positives (14); NVLT: 
Difference of true and false positives (15). 
Cognitive impairment classification 
The classification criteria that were identified in the review part of this paper were adapted 
so that they could be applied on the present 15 parameters. For example, if the reviewed 
criteria required 3 out of 12 parameters to be abnormal, the equivalent would be 4 out of 15 
in our data. To adapt criteria that accounted for cognitive domains (e.g., abnormal 
parameters in at least two domains), the following domains were defined in our test battery: 
attention (TAP-Alertness, TAP-Divided Attention), memory (DCS, AVLT, VLT, NVLT), 
immediate recall (AVLT-trial 1-5, DCS, VLT, NVLT), delayed recall (ROCF, AVLT-trial7, AVLT-
recognition), and executive function (TAP-Flexibility). 
Statistical analysis 
Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS 
Inc., Chicago, IL, USA). Relevant outcomes were rates of cognitive impairment and inter-rater 
reliability defined as percentage of patients classified as impaired/unimpaired by two or 
more classification strategies. Group comparisons of impairment rates were assessed using 
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Fisher’s exact test. Inter-rater reliability was assessed using Kendall’s W. Group comparisons 
of inter-rater reliabilities were tested using repeated measures ANOVA with Bonferroni 
corrected pair wise comparisons. The alpha error level was set at 0.05. 
2.3. Results 
2.3.1. Review 
Out of 921 screened records, 68 articles were included into the review (Figure 3). 70 
classification criteria could be identified and grouped into 20 distinct approaches (Table 2; 
Table e1). Cognitive performance was mostly evaluated by variations of standard test 
batteries (BRB-N: 31, MACFIMS: 7, other: 5, nonstandard test battery: 27). Three basic 
classification strategies are in use:  
Strategy 1: Critical number of abnormal parameters 
59 criteria utilized a classification strategy based on the number of abnormal parameters, 
i.e., a person is considered cognitively impaired if he scores abnormally low on a predefined 
number of scores. Cut-offs for abnormality varied between one and two standard deviations. 
The 1.5 / 1.68 SD (n = 30) and 2 SD (n = 25) cut-offs were equally common, whereas 1 SD (n = 
4), and combinations of 1.5 and 2 SD (n = 2) were used less often. On average, the included 
studies defined a rate of 22 ± 9.4 % (range: 6 – 5 0%) of abnormal test parameters to be 
critical for impairment. In six studies, the authors varied the classification strategy by 
grouping the parameters into tests or domains (e.g. attention, information processing, 
memory, executive function). Thus, they ensured that only patients who performed 
abnormally in multiple tests or domains are considered cognitively impaired. Of the 51 
criteria that could be evaluated in respect of stringency (i.e., not domain-specific, no 
combined cut-off), 5 were classified liberal, 17 fair, and 29 conservative. 
Strategy 2: Composite score 
In eight articles, the formation of composite indices were described which can be used for 
impairment classification. In three cases, the mean of all normalized scores was used. In one 
paper, the composite was computed as the sum of only those normalized parameters that 
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highly intercorrelated and had a mean below T = 50. In three other papers, domain-specific 
means of normalized scores were used. One other approach was used in which a “global 
cognitive impairment index” was computed by grading each test score in respect to mean 
and standard deviations of normative data (Camp et al., 1999). 
Strategy 3: Combined criteria 
In three papers, classification of CI was based on a combination of composite scores and 
number of abnormal parameters. 
 
Figure 3. Flowchart of literature review
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Table 2. Summary of the 70 reviewed classification criteria 
n1 
SD  
cut-off
2 Criterion (stringency
3) %CI4 
Strategy 1: Critical number of abnormal parameters5 
18 2.0 abnormality in 24±11% parameters (conservative) 35±13 
14 1.5 abnormality in 18±2% parameters (fair) 46±11 
10 1.5 abnormality in 30±6% parameters (conservative) 40±12 
3 2.0 
abnormality in 17±11% parameters in at least two different cognitive 
domains 
26±2 
2 1.5 abnormality in 13% parameters (liberal) 48±2 
2 2.0 abnormality in 6% parameters (liberal) 51±7 
2 
1.5 & 
2.0 
15% parameters ≥ 2 SD and 15% parameters ≥ 1.5 SD; or 44% 
parameters  ≥ 1.5 SD 
50±14 
2 1.5 20% of tests abnormal (i.e. abnormality in 1 parameter of each test) 52±11 
1 1.0 abnormality in 30% parameters (fair) 22 
1 1.0 abnormality in 17% parameters (liberal) 94 
1 2.0 abnormality in 8% parameters (fair) 29 
1 1.5 
abnormality in 13% parameters in at least two of the four main 
functional areas (psychomotor speed, attention, memory, executive 
function) 
48 
Strategy 2: Composite score5 
2 1.5 abnormal average of normalized parameters 15±13 
2 1.5 
abnormality in 25-29% cognitive domain scores (average of associated 
normalized parameters) 
31±18 
1 1.0 abnormal average of normalized parameters 28 
1 1.5 
abnormal graded sum (grading system for each parameter: 1-2 SD below 
normative mean [=1], more than 2 SD [=2] ) 
40 
1 1.5 
abnormal sum of those normalized parameters that highly intercorrelate 
[Cronbach alpha=.76] and have a mean below T=50) 
45 
1 
0.5 & 
1.0 
abnormal average of normalized parameters (0.5 SD) and one out of 
three cognitive factor scores (based on factor analysis) abnormally (1 
SD) 
38 
Strategy 3: Combined criteria5 
2 
1.5 & 
2.0 
average of parameters believed to be most sensitive to CI in MS (i.e., 
SDMT, PASAT, BVMT, and CVLT; cut-off 1.5 SD); or 10% parameters (2 
SD) and 20% parameters (1.5 SD), or 20% parameters (2 SD) across all 
parameters 
42±9 
1 
0.33 
& 2.0 
sum of normalized parameters (0.33 SD); or abnormality in 33% 
parameters (2 SD) 
67 
1: Number of associated criteria 
2: "1.5 SD" includes also cut-offs based on the 5th percentile 
3: When possible the criteria were classified in respect of their stringency (liberal, fair, or conservative). This was based on false positive 
rates, i.e., on how many parameters healthy people fail on a cut-off of 1, 1.5, and 2 SD[10]. Criteria were considered fair if CI was defined as 
performance below 1 SD on 32%±6.4%, on less than 25.6% as liberal, and on more than 38.4% as conservative. The respective figures were 
17±3.4% for the 1.5 SD / 5th percentile cut-off, and 7.5±1.5% for the 2 SD cut-off 
4: Percentage of cognitive impairment revealed in the reviewed papers utilizing the associated classification criterion (mean±SD) 
5: Classification can be based on (1) the number of abnormal test parameters, (2) on the formation of a composite index, or (3) on a 
combination of the first two 
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Classification strategy and CI  
Across all reviewed papers, an average of 41 ± 15% (range: 6 – 94 %) of patients were 
classified as cognitively impaired (Table 2). Criteria based on Strategy 1 reported a 
prevalence of 42 ± 15 %. Papers utilizing Strategy 2 reported CI in 30 ± 14 % and papers 
utilizing Strategy 3 reported CI in 50 ± 16 %. The differences in the impairment rate were not 
statistically significant (F(2,69) = 2.85, p = .07). 
Stringency and CI 
Stringency had an effect on impairment rate (F(2,50) = 5.52, p < .01). Prevalence rates were 
higher following liberal (58 ± 20 %) compared to conservative criteria (37 ± 13 %, p < .01). 
There was no difference between fair (44 ± 13 %) and liberal criteria (p = .13), and between 
fair and conservative criteria (p = .22). The continuous stringency measure correlated with 
percentage of impairment (N = 51, r = -43, p < .01). 
Stringency and disease duration 
Stringency had an effect on disease duration (F(2,43) = 6.37, p < .01). Disease duration was 
higher in conservative (11.2 ± 7.1 years) compared to liberal (2.4 ± 4.3 years, p < .05) and fair 
(6.0 ± 4.0 years, p < .05) criteria. There was no difference between the liberal and fair criteria 
(p = .49). The continuous stringency measure correlated with disease duration (N = 44, r = 
.48, p < .01). 
2.3.2. New Data 
Disease stage and CI 
When applying the 20 classification criteria on our test battery and subjects (Table 3), we 
found a group effect on cognitive impairment (F(3,80) = 3316.28, p < .0001) with a higher 
prevalence in late (40 ± 18 %, range: 4 – 81 %) compared to early (12 ± 17 %, range: 0 – 68 %, 
p < .0001), control early (5 ± 10 %, range: 0 – 44 %, p < .0001), and control late MS (9 ± 15 %, 
range: 0 – 64 %, p < .0001). There were no differences between the other groups (all p > .4). 
  
  
Page | 30  
Classification strategy and CI 
Strategy had an effect on impairment rate (F(2,80) = 894.73, p < .05). The prevalence derived 
from criteria associated to Strategy 1 (20 ± 22 %) was higher compared to Strategy 2 (9 ± 15 
%), p < .05). There were no differences between Strategy 1 and Strategy 3 (19 ± 20 %, p = 
.99), and Strategy 2 and Strategy 3 (p = .27). 
Classification criteria and CI in patients vs. controls 
18 out of 20 criteria resulted in higher rates in late MS versus matched controls, whereas 
only 2 did so in early MS versus matched controls (Table 3). The prevalence rates, according 
to 16 criteria, were lower in early compared to late MS.
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Table 3. Common classification criteria for cognitive impairment applied on own data of 77 MS patients and 75 matched controls: Prevalence rate of 
cognitive impairment. 
SD 
Cut-
off1 
Criterion (stringency)2 
Exemplary  
publication 
% cognitive impairment 
early stage3 late stage4 
MS 
control  
group 
p5 MS 
control  
group 
p5 
Strategy 1: Critical number of abnormal parameters 
1 abnormality in 13% parameters (liberal) (Achiron & Barak, 2003) 68% 44% .15 81% 64% .08 
abnormality in 33% parameters (fair) (Patti et al., 2009) 0% 4% 1 46% 6% .0001 
1.5 abnormality in 13% parameters (liberal) (Glanz et al., 2007) 32% 4% .02 58% 22% .0001 
abnormality in 20% parameters (fair) (Nocentini et al., 2006) 8% 0% .49 46% 8% .0001 
abnormality in 33% parameters (conservative) (Amato et al., 2006) 0% 0% N/A 21% 2% .001 
 abnormality in 13% parameters in at least two of the 
three main functional areas (attention, memory, 
executive function) 
(Smestad et al., 2010) 20% 4% .19 44% 6% .0001 
 25% of tests abnormal (i.e. abnormality in 1 parameter of 
each test) 
(Deloire et al., 2006) 28% 4% .05 62% 18% .0001 
2 abnormality in 6.7% parameters (liberal) (Faiss et al., 2014) 36% 16% .20 54% 16% .0001 
abnormality in 13% parameters (conservative) (Feuillet et al., 2007) 4% 0% 1 35% 2% .0001 
abnormality in 20% parameters (conservative) (Zipoli et al., 2010) 0% 0% N/A 21% 0% .001 
 
abnormality in 20% parameters in at least two different 
cognitive domains 
(Zivadinov, De Masi, et al., 2001) 4% 0% 1 25% 0% .0001 
  
abnormality in 13% parameters (≥ 2 SD) and in 13% 
parameters (≥ 1.5 SD); or in 40% parameters (≥ 1.5 SD) 
(Benedict, Bruce, et al., 2006) 4% 0% 1 35% 2% .0001 
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Strategy 2: Composite score 
com-
po- 
site 
average of normalized parameters (cut-off 1.0 SD) (Achiron et al., 2013) 0% 0% N/A 21% 0% .001 
average of normalized parameters (cut-off 1.5 SD) (Weinges-Evers et al., 2010) 0% 0% N/A 4% 0% .50 
abnormality in 25% cognitive domain scores (average of 
associated normalized parameters; cut-off 1.5 SD)6 
(Khalil et al., 2011) 4% 0% .49 33% 4% .0001 
graded sum (grading system for each parameter: 1-2 SD 
below normative mean [=1], more than 2 SD [=2]) (cut-off 
5th percentile of controls) 
(Sánchez, Nieto, Barroso, Martín, & 
Hernández, 2008) 
0% 0% N/A 44% 2% .0001 
average of normalized parameters (cut-off 0.5 SD) and 
one out of three cognitive factor scores (based on factor 
analysis7) (cut-off 1 SD) 
(Denney, Lynch, & Parmenter, 2008) 4% 4% 1 31% 4% .0001 
sum of those normalized parameters that highly 
intercorrelate [cronbach alpha=.76] and have a mean 
below T=50 (cut-off 1.5 SD on regression based residuals) 
(Mathiesen et al., 2006) 8% 0% .49 54% 10% .0001 
Strategy 3: Combined criteria 
comb-
ined 
sum of normalized parameters (cut-off 0.33 SD); or 
abnormality in 33% parameters (cut-off 2 SD) 
(Lazeron et al., 2005) 12% 16% 1 58% 20% .0001 
average of parameters believed to be most sensitive to CI 
in MS (i.e., alertness, divided attention, DCS, and AVLT; 
cut-off 1.5 SD); or 6.7% parameters (cut-off 2 SD) and 20% 
parameters (cut-off 1.5 SD), or 20% parameters (cut-off 2 
SD) across all parameters8 
(Benedict et al., 2004) 8% 0% .49 37% 2% .0001 
1 "1.5 SD" includes also cut-offs based on the 5th percentile 
2 stringency based on false positive rates (i.e., on how many parameters healthy people fail on a cut-off of 1, 1.5, and 2 SD (Schretlen et al., 2008)), the criteria were labeled as liberal, fair, or conservative (see methods for details). 
3: disease duration < 2 years 
4: disease duration >12 years 
5: p-values of Fisher's exact test, testing for differences in prevalence rate in patients vs. controls 
PP=Primary Progressive MS; TP= Transitional Progressive MS; SP=Secondary Progressive MS; RR=Relapsing Remitting; CIS=Clinically isolated syndrome 
6: domain scores: (1) immediate recall: AVLT trial 1-5, DCS, VLT, NVLT; (2) delayed recall: AVLT difference trial 5 and delayed free recall, AVLT recognition, ROCF delayed receall; (3) mental processing speed: alertness, divided attention; (4) 
executive function: flexibility. 
7: varimax rotated factor solution: (1) AVLT, VLT, DCS-storage; (2) alertness; (3) divided attention omissions, ROCF-recall, divided attention errors; (4) divided attention errors, divided attention RT; (5) DCS-learning, flexibility 
8: DCS=Diagnosticum fuer Cerebralschaedigung, AVLT=Auditory Verbal Learning Test 
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Number of parameters below different SD cut-offs 
To clarify whether very low, moderately low, or slightly low performances discriminate 
better between the groups of MS and controls, the number of performances that were 1 - 
1.5 SD, 1.5 - 2 SD, and more than 2 SD below the normative mean were compared. All ranges 
of low performances as assessed by the aforementioned SD cut-offs increased in late MS 
compared to controls, whereas in early MS only a trend for very low performances could be 
revealed (Table 4). 
 
Table 4. Number of parameters that are below different SD cut-offs 
cut-offa 
early stage late stage 
MS control   MS control   
mean SD mean SD pb mean SD mean SD pb 
1-1.5 SD 0,92 0,76 1,20 1,04 0.39 2,08 1,41 1,12 1,08 0.001 
1.5-2SD 0,64 0,76 0,32 0,48 0.14 1,40 1,49 0,70 1,04 0.011 
>2SD 0,40 0,58 0,16 0,37 0.10 1,21 1,45 0,18 0,44 0.000 
a: Number of parameters that were at least 1SD, but less than 1.5SD below the normative mean (1-1.5 SD), or at least 1.5SD, but less than 
2 SD below the normative mean (1.5-2SD), or at least 2SD below the normative mean (>2SD)  
b: p-values of Mann-Whitney Test 
 
Inter-rater reliability of classification 
The classification of all 20 criteria resulted in a moderate inter-rater reliability (Kendall’s W 
[N = 20, df = 74] = 0.6, p < 0.0001). Similar inter-rater reliabilities were achieved within 
criteria of Strategy 1 (Kendall’s W *N = 12, df = 74] = 0.6, p < 0.0001) and Strategy 2 
(Kendall’s W *N = 6, df = 74] = 0.6, p < 0.0001). On average 77 % (SD = 12, range: 25 - 100) of 
MS patients were classified the same by two separate criteria (Table 5). Classification of 
criteria with a comparable outcome (i.e., 4 criteria with 20 – 36 % CI in early MS; 4 criteria 
with 35 – 46 % CI in late MS), resulted in strong inter-rater reliabilities (Kendall’s W *N = 4, df 
= 24] = 0.71; Kendall’s W [N = 4, df = 51] = 0.84, both p < .0001). This means that in early MS 
68 %, and in late MS 81 %, of patients were classified consistently across the four 
comparable criteria. 
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Table 5. Common classification criteria for cognitive impairment applied on own data of 77 MS patients: Inter-rater reliability (% of agreement between two separate criteria) 
Criterion
1
 A B C D E** F* G H I J* K** L M N* O* P Q R S* T* 
  % CI
2
 76.62 50.65 49.35 48.05 42.86 38.96 36.36 33.77 31.17 29.87 27.27 24.68 24.68 24.00 22.08 18.18 14.29 14.29 14.29 2.63 
A 76.62 
 
74 73 66 66 62 60 57 55 53 51 48 48 43 45 42 38 38 38 25 
B 50.65 74 
 
96 74 82 81 86 83 78 77 77 71 71 69 71 68 64 64 64 51 
C 49.35 73 96 
 
75 81 73 82 84 79 78 79 75 77 71 66 69 65 65 66 53 
D 48.05 66 74 75 
 
71 73 70 73 75 77 79 77 77 64 66 70 66 66 66 54 
E** 42.86 66 82 81 71 
 
88 78 86 81 79 79 74 74 75 79 69 71 69 71 59 
F* 38.96 62 81 82 73 88 
 
77 87 87 86 83 78 78 76 78 75 75 75 75 63 
G 36.36 60 86 82 70 78 77 
 
79 82 83 78 78 78 73 75 82 75 75 75 66 
H 33.77 57 83 84 73 86 87 79 
 
90 88 94 86 86 87 83 82 81 81 81 68 
I 31.17 55 78 79 75 81 87 82 90 
 
99 88 91 91 87 83 84 83 83 83 71 
J* 29.87 53 77 78 77 79 86 83 88 99 
 
90 92 92 88 82 86 84 84 84 72 
K** 27.27 51 77 78 79 79 83 78 94 88 90 
 
92 92 85 84 87 87 87 87 75 
L 24.68 48 71 75 77 74 78 78 86 91 92 92 
 
100 88 87 91 90 90 90 78 
M 24.68 48 71 75 77 74 78 78 86 91 92 92 100 
 
88 87 90 90 90 90 78 
N* 24.00 43 69 71 64 75 76 73 87 87 88 85 88 88 
 
80 81 88 88 91 79 
O* 22.08 45 71 70 66 79 78 75 83 83 82 84 87 87 80 
 
82 90 82 87 80 
P 18.18 42 68 69 70 73 74 82 82 84 86 88 91 91 81 86 
 
91 91 88 84 
Q 14.29 43 69 70 69 71 75 78 86 88 90 87 92 90 93 90 88 
 
92 95 83 
R 14.29 38 64 65 66 69 75 75 81 83 84 87 90 90 88 82 91 90 
 
92 88 
S* 14.29 38 64 65 66 71 75 75 81 83 84 87 90 90 91 87 92 95 92 
 
88 
T* 2.63 25 51 53 54 59 63 66 68 71 72 75 78 78 79 80 84 88 88 88 
 
 
mean 51.9 74.0 74.8 70.7 75.6 77.3 76.6 82.1 82.9 83.2 82.9 83.0 82.9 79.2 78.6 79.6 79.5 78.9 79.5 69.2 
1: Criterion is either based on a critical number of abnormal parameters (strategy 1), or on the formation of composite scores ("*"; strategy 2), or on a combination of composite scores and critical number of abnormal parameters ("**"; strategy 3):  
[A] abnormality in 13% parameters (cut-off 1SD); [B] 25% of tests abnormal (i.e. abnormality in 1 parameter of each test; cut-off 1.5SD); [C] abnormality in 13% parameters (cut-off 1.5 SD); [D] abnormality in 6.7% parameters (cut-off 2SD); 
[E] sum of normalized parameters (cut-off 0.33 SD); or abnormality in 33% parameters (cut-off 2 SD);[F] sum of those normalized parameters that highly intercorrelate [cronbach alpha=.76] and have a mean below T=50 (cut-off 1.5 SD on regression 
based residuals); [G] abnormality in 13% parameters in at least two of the three main functional areas (attention, memory, executive function, cut-off 1.5SD) ;[H] abnormality in 20% parameters (cut-off 1.5SD);[I] abnormality in 33% parameters (cut-off 
1SD) ; [J] graded sum (grading system for each parameter: 1-2 SD below normative mean [=1], more than 2 SD [=2]) (cut-off 5th percentile of controls); [K] average of parameters believed to be most sensitive to CI in MS (i.e., alertness, divided attention, 
DCS, and AVLT; cut-off 1.5 SD); or 6.7% parameters (cut-off 2 SD) and 20% parameters (cut-off 1.5 SD), or 20% parameters (cut-off 2 SD) across all parameters; [L] abnormality in 13% parameters (cut-off 2 SD); *M+ abnormality in 13% parameters (≥ 2 SD) 
and in 13% parameters (≥ 1.5 SD); or in 40% parameters (≥ 1.5 SD); [N] abnormality in 25% cognitive domain scores (average of associated normalized parameters; cut-off 1.5 SD); [O] average of normalized parameters (cut-off 0.5 SD) and one out of 
three cognitive factor scores (based on factor analysis) (cut-off 1 SD); [P] abnormality in 20% parameters in at least two different cognitive domains (cut-off 2 SD); [Q] abnormality in 33% parameters (cut-off 1.5 SD); [R] abnormality in 20% parameters 
(cut-off 2SD); [S] average of normalized parameters (cut-off 1.0 SD); [T] average of normalized parameters (cut-off 1.5 SD). 
2: Criteria are sorted by percentage of cognitive impairment revealed by each criterion. 
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Inter-rater reliability between Strategy 1 and Strategy 2 
The six criteria utilizing composite indices differed in their agreement with classification 
based on criteria of strategy 1 (F(5,55) = 350.57, p < .0001). The graded sum approach 
(Sánchez et al., 2008) showed the highest agreement (83 ± 3 %), whereas the approach 
based on a 1.5 SD cut-off of the averaged normalized parameters (Weinges-Evers et al., 
2010) showed the least agreement (66 ± 5 %). 
2.4. Discussion 
The present study was driven by the question of how reliable the classification of cognitive 
impairment in MS is across common criteria. First, a review of classification criteria used by 
different researchers was provided. Then the different approaches were applied to the 
neuropsychological data of early and late MS patients and the outcome compared in terms 
of prevalence rate and inter-rater reliability. 
The review revealed 20 distinct approaches that have been used to classify cognitive 
impairment in MS. They can be subdivided into three strategies. The first strategy is based 
on the number of abnormal test parameters, the second on the formation of a composite 
index, and the third is a combination of the first two. The majority of researchers utilize the 
first strategy but with differences in the cut-off for abnormal performance and in the critical 
number of abnormal performances. Thus, in spite of the suggested criteria of a fifth 
percentile cut-off on about 20 % of tests or test parameters (Benedict, 2009), a range of 
other criteria are still in use. 
On average, the reported prevalences confirm the popular figure of 40% (Rao et al., 1991) 
but, as expected, studies utilizing more liberal criteria report higher prevalence rates than 
those with fair or conservative criteria. Moreover, our data shows that liberal criteria are 
more frequently utilized in samples with shorter disease durations. This bias makes it 
difficult to compare results on CI in early and late disease stages. It also suggests that CI may 
be overemphasized in the early disease stage. However, more than half of the 70 reviewed 
criteria applied a fair or conservative stringency on 1.5 or 2 SD cut-offs. 
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Combined criteria and criteria based on composite scores are rarely used. There is no 
consensus on how to define a composite score and we found variations from a simple 
average of all cognitive test parameters to factor analysis based solutions. As shown before, 
studies that took averaged standard scores as a composite find low rates of cognitive 
impairment (Olazarán et al., 2009), whereas the outcome of a composite score based on a 
grading system of failed parameters (Camp et al., 1999; Sánchez et al., 2008) is more 
comparable. 
The sample of late MS patients demonstrated the profound effect that the choice of 
classification strategy has on the prevalence rate of cognitive impairment. Adopting the set 
of previously published criteria we found between 4 % and 81 % impaired patients. This 
result further challenges the reliability of the concept of cognitive impairment. The situation 
is complicated by the fact that, except for the very conservative or liberal ones, most 
strategies’ outcomes differentiate between patients and controls. 
Interestingly, no particular cut-off seems to be beneficial, which is due to the fact that the 
cut-off alone does not determine the prevalence rate, but rather the cut-off in combination 
with the required number of parameters below that cut-off (Schretlen et al., 2008). Using 
criteria in which the number and cut-off are adjusted at a similar level, we found significant 
statistical agreement across different cut-offs, i.e. more than two third of the patients are 
classified consistently. From this point of view, it is acceptable to use any of the three cut-
offs, as long the number of critical parameters is adjusted. For this adjustment, this study 
confirms previously published data (Schretlen et al., 2008), i.e., that out of all parameters in 
a test battery at least 32 % should fall below 1 SD, 17 % below 1.5 SD, and 7.5 % below 2 SD, 
because then patients are well distinguished from controls and prevalence rates are 
comparable to the literature. 
In the new data we could confirm that criteria that are based on composite scores result in 
lower rates of CI compared to criteria that are based on abnormality of parameters. This 
primarily applies to criteria that utilize an average of all standard scores (e.g., mean z). 
However, applying a very liberal cut-off (0.5 SD) on this average, leads to a classification 
agreement of 90 % with the common 1.5 SD cut-off on 20 % parameters (ROC analysis: area 
under the curve = .97, data not shown). This shows that the mean of standard scores is a 
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reliable alternative in classifying cognitively impaired patients. Other reliable alternatives are 
the compound measure defined as a graded system first introduced by Camp and colleagues 
(Camp et al., 1999; Sánchez et al., 2008), and the regression-based approach by Mathiesen 
and colleagues (2006). 
The findings in the early disease stage are less straightforward. As in the late stage, the 
impact of the utilized classification strategy is considerably high (rates from 0 % to 88 %). 
However, less than 10 % of patients were cognitively impaired following fair and 
conservative criteria on either cut-off, as well as composite scores, suggesting that these 
strategies are too stringent to investigate early cognitive impairment in MS. By using more 
liberal criteria, the rates can be increased, but - except for the 1.5 SD cut-off - they do not 
distinguish from false positive rates in healthy controls. Moreover, the effect of the liberal 
1.5 SD criterion was primarily due to the extraordinary performance of controls for early MS 
that failed 5 times fewer on this criterion than controls for late MS. Compared to a more 
representative control group of early and late controls, only the liberal 2 SD criterion might 
reveal increased prevalence in early patients (p = .08, data not shown). Thus, whereas the 
1.5 and 2 SD cut-offs in liberal criteria are to some extent specific and concordant, the 1 SD 
cut-off is not, no matter how stringently it is handled. Accordingly, our data suggests that 
patients in the early stage are characterised by an increase in very low performances (> 2 SD) 
rather than by an increased number of borderline or slightly abnormal performances. 
The data on inter-rater reliability suggests that a high agreement in classification of CI in MS 
can be achieved with very different classification strategies. It seems far more important to 
correct for false positives, especially in respect of multiple comparison errors in larger test 
batteries. This can be done by employing a control group. Alternatively, the aforementioned 
adjustments for different SD cut-offs can also be used to calculate cut-offs on composite 
scores. For example, the fifth percentile cut-off on 20 % parameters equals a mean z of -0.3. 
Altogether, the data indicates that the stringency is the key factor in classifying CI in MS that 
needs to be better homogenized between future studies. An additional differentiation of 
cognitive impairment into mild, moderate, and severe forms based on the aforementioned 
criteria can facilitate comparability (Amato et al., 2001). 
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The impact of methodology we found on the classification of cognitive impairment in MS 
complements the work of Walker and colleagues (2011), who reported similar findings on 
interpretation of longitudinal cognitive data. The present results are also in line with 
research on the classification of mild cognitive impairment (MCI) in geriatric patients. Here, a 
similar high prevalence range between common criteria has been reported (i.e., 9 % to 74 %) 
(Jak & Bondi, 2009). Additionally, as supported by the findings of this paper, a good 
correspondence of classification in two out of three patients occurs if two criteria lead to 
comparable prevalence rates. Remarkably, conservative strategies seem to be more reliable, 
based on a better longitudinal stability and significant associations with external markers 
(e.g., medial temporal atrophy) (Schinka & Loewenstein, 2010). Accordingly, only the 
conservative criterion in Zipoli et al.’s study (Zipoli et al., 2010) (i.e., 30 % abnormal 
parameters below a 2 SD cut-off) had predictive value for conversion from CIS to MS. 
The present study suggests that some of the reported prevalence rates of cognitive 
impairment in early disease stages could be overestimated due to the usage of liberal 
criteria (Achiron & Barak, 2003; Deloire et al., 2006; Glanz et al., 2007). It, therefore, helps to 
explain differences, as in Weinges-Evers et al. (2010) who only found 6 % and Deloire and 
colleagues (2006) who found 60 % of patients cognitively impaired in two comparable 
samples of early MS patients. Applying their classification criteria on our data contrasts rates 
of 0 % and 28 %.  
The main limitation of our study is the small sample size of the early MS group. Compared to 
other studies, we recruited a sample in which most patients appeared cognitively preserved. 
Following the more stringent criteria, we could detect impairment in neither the early MS 
nor the control group and therefore cannot exclude the possibility that our sample 
contained no one suffering from cognitive impairment. A recent study is in line with that 
notion, showing early impairment only in verbal fluency, but not in working and verbal 
episodic memory, flexibility, and information processing speed (Brissart, Morele, Baumann, 
& Debouverie, 2012). Although our recruitment was mostly unbiased (subjects chosen by 
demographic criteria to match with late MS patients and not by probable cognitive 
impairment), we did exclude patients with severe depression or fatigue, both of which are 
associated with cognitive impairment (Patti, 2009). Even though depression and fatigue are 
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prevalent in MS, the cut-offs used in this study were considerably higher than usual (CES-D: 
39 compared to 23, WEIMUS: 32 compared to 52) and only two patients had to be excluded 
due to fatigue. Our test battery assessed executive functions as part of complex tests, but 
not specifically those aspects that are typically impaired in MS, i.e., verbal fluency or card 
sorting. However, executive deficits are rare in early stages (Henry & Beatty, 2006) and the 
inclusion of those tests should not have had much effect on prevalence rates. 
It is also important to keep in mind that only one of many factors that contribute to 
impairment classification in neuropsychological practice was investigated. Usually, test 
performance is evaluated under consideration of other factors such as pre-morbid cognitive 
performance, motivational factors, behavioural observations, external information from 
friends and relatives, and overall coherence. However, these factors are hardly part of 
studies on cognitive impairment.  
The impact of cognitive impairment on daily function based on different criteria remains 
undetermined. For example, it is likely that liberal criteria classify some patients as 
cognitively impaired who are not affected by it in their social, occupational, and 
psychological functioning. In fact, in more subtle cases the ecological validity of CI 
classification is the major problem. However, there are no reliable measures of ecological 
validity available and perceived cognitive deficits are often associated with depression 
(Benedict et al., 2004). Also, even though cognitive impairment in MS further deteriorates 
(Amato et al., 2001), it is unclear whether the same holds true for CI based on liberal criteria 
in early MS stages, i.e., is the classification stable over time and does it have predictive value 
for further cognitive deterioration? 
In conclusion, the high prevalence range between common classification strategies is 
primarily the result of differences on the liberal to conservative stringency axis. In contrast, 
conceptually different classification criteria, such as composite index vs. multiple tests, 
domain-specific vs. domain-unspecific and high vs. low SD cut-off, provide concordant 
classifications. Nonetheless, in early disease stages, in which relatively well preserved 
cognitive functions can be expected, strategies that rely on a liberal stringency and higher SD 
cut-offs provide sufficiently large percentages of impaired patients. It is important to note 
that these are with uncertain significance due to false positives. Here, data from a matched 
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control group should be acquired. In later stages, other criteria, including a composite index, 
are reliable alternatives to the common 1.5 SD cut-off on 20 % of tests or test parameters 
(Benedict, 2009). To avoid these classification issues, one could use current standardised test 
batteries for MS recommended by the international consortium, i.e., MACFIMS, BRB-N, 
BICAMS (Langdon et al., 2012). 
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3. Study two: Information processing deficits as a driving 
force for memory impairment in MS: A cross-sectional 
study of memory functions and MRI in early and late 
stage MS. 
3.1. Introduction 
Memory impairment (MI) can affect up to 65% of patients with multiple sclerosis (MS). In 
the past years it was found that significant MI can already be present in the first years after 
MS onset (Grant, McDonald, Trimble, Smith, & Reed, 1984; Schulz et al., 2006; Sicotte et al., 
2008) and that structural (Koenig et al., 2014; Pardini et al., 2014; Planche et al., 2015; 
Sicotte et al., 2008) and functional alterations (Hulst et al., 2015) of the hippocampus 
correlate with the degree of MI. 
However, several studies reported conflicting results demonstrating well preserved memory 
performance in the early MS stage (Kern et al., 2015; Nygaard et al., 2015; Panou, 
Mastorodemos, Papadaki, Simos, & Plaitakis, 2012; Pardini et al., 2014; Roosendaal et al., 
2010), a lack of correlation between hippocampal alterations and MI (Anderson et al., 2010; 
Debernard et al., 2015; Kern et al., 2015; Roosendaal et al., 2010) or correlations with only 
some memory functions (Benedict, Ramasamy, Munschauer, Weinstock-Guttman, & 
Zivadinov, 2009; Kiy et al., 2011). The reasons for these inconsistencies are not clear and 
hinder the understanding of the underlying mechanism of MI in MS. 
One source of confound might be related to methodology. First, it is possible that the 
correlations between memory performance and MR-based parameters are confounded with 
disease stage. More specifically, the effect of focal damage on memory may be more 
pronounced in early stages, whereas in later stages the effect of global tissue loss plays a 
more important role (Planche et al., 2015; Schoonheim, Meijer, & Geurts, 2015). Secondly, 
MI could be confounded with slowed information-processing (IPS), which is a core deficit in 
MS and basic cognitive function affecting learning and memory (Costa, Genova, DeLuca, & 
Chiaravalloti, 2017). In other words, an association of MI with slowed IPS could provide an 
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alternative explanation to direct destructions in memory specific tracts such as the 
hippocampus (Sacco et al., 2015). Finally, the use of different test paradigms for memory 
assessment could have contributed to the heterogeneity of previous results (Anderson et al., 
2010). In fact, as an alternative to the international standard screening tests of MS-related 
MI (i.e., SRT, SPART, BVMT-R, CVLT), locally validated memory assessments have been used 
(Longoni et al., 2015; Roosendaal et al., 2010; Schulz et al., 2006) as well as extensive 
memory test batteries (Anderson et al., 2010; Grant et al., 1984; Panou et al., 2012) and 
shorter screenings (Sicotte et al., 2008). 
The present study was designed to evaluate MI in MS with an emphasis on the 
aforementioned methodological aspects, i.e., contrasting early and late disease stage, 
controlling for a potential IPS deficit, and utilizing multiple memory test paradigms. In a first 
step MI was assessed in individually matched patients with early versus late MS by using five 
memory tests and including an individually matched healthy control group. MI was 
discriminated from performance in three tests constituting IPS. In a second step the 
correlations with MRI were evaluated at both disease stages including T1/T2 lesion load, 
hippocampus volume, brain volume, and cortical thickness. 
3.2. Methods 
The present paper reports results of a multi-center, cross-sectional study that was designed 
to compare visual processing capacity, cognitive functions and associated MRI markers in 
early versus late MS. Memory was the cognitive function of primary interest in this study and 
therefore a key element of the study design was the implementation of five different tests of 
episodic memory. Also, the study included patients with disease durations of either less than 
2 years or more than 12 years in order to contrast MI emerging from very early MS-related 
effects and MI emerging from later deterioration (Amato et al., 2001). To control for possible 
confounders, patients were recruited as individual pairs matched for age at disease onset, 
gender, and education. 
The study was approved by the Ethical Committee of the Saechsische Landesaerztekammer 
(EK-BR-24/10-1) and all subjects provided written informed consent prior to participation. 
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Subjects 
Seventy-seven patients (Table 6) diagnosed with clinically isolated syndrome, RRMS, or 
SPMS (Polman et al., 2005) were recruited in five MS centres in Germany (Wermsdorf, Halle, 
Magdeburg, Rostock, Teupitz) between February and September 2011 and assigned to two 
matched groups, one group with disease duration less than 2 years from the first clinical 
event (EMS) and another group with disease duration longer than 12 years (LMS). Patients 
were individually matched with respect to age at disease onset (+/-3 years), gender and 
education, i.e., after inclusion of one EMS-patient, two matching LMS-patients were 
recruited. More LMS-patients were recruited to account for the higher variety of structural 
and cognitive changes at later disease stages. Each site was instructed to recruit sets of 3 
matched patients. For this purpose, outpatients were consecutively screened at each site for 
potential eligibility and matching. When a set was identified, the corresponding patients 
were invited for inclusion. However, if a site was not able to recruit a full set, the patients’ 
characteristics were entered into a centralized recruitment spread sheet and the other sites 
were given the opportunity to recruit matching patients to the set.  
Exclusion criteria were a relapse or corticosteroid treatment 4 weeks prior to 
neuropsychological assessment, visual acuity <0.2, severe fatigue (Wuerzburger Fatigue 
Inventory for MS ≥52 (Flachenecker et al., 2006)) or depression (Center for Epidemiological 
Studies Depression Scale ≥39 (Hautzinger & Bailer, 1993)), alcohol abuse, pregnancy, other 
relevant serious neurological and internal medical diseases as well as exclusion criteria for 
MRI. 
Additionally, 75 individually matched healthy control subjects were recruited by the MS 
centres mentioned above and a sixth centre in Jena, Germany with corresponding age (+/-3 
years), gender and education and assigned to two control groups (cEMS, cLMS). The same 
exclusion criteria were applied. All subjects received financial compensation for their travel 
expenses. 
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Table 6. Clinical and demographic variables. 
 MS controls pa 
  EMS LMS cEMS cLMS EMS 
vs. 
LMS 
EMS 
vs. 
cEMS 
LMS 
vs. 
cLMS 
N 25 52 25 50    
Sex (m/f) 8/17 16/36 8/17 14/36 1 1 ,830 
Age (years, mean±SD) 29,2±6,7 45,3±7,8 28,6±7,3 44,4±7,7 ,000 ,734 ,591 
Age at disease onset (years, 
mean±SD) 
28.2±7.0 28.7±7.1   ,777   
Disease duration (years, 
mean±SD) 
1.0±0.8 16.5±5.2   ,000   
Relapses past year (mean±SD) 1.5±1.9 0.3±0.7   ,000   
Multifocal involvement at 
onset 
24.0% 23.0%   1   
EDSS (Median [min-max]) 2.0 [0-6] 3.3 [0-8]   ,000   
Using MS medication 96.0% 88.5%   ,257   
Education ≥12 years 36.0% 28.8% 36.0% 26.0% ,603 1 ,830 
Depression (CES-D, mean±SD) 12,8±9,7 13,0±9,2 7,4±4,7 8,8±8,2 ,910 ,017 ,017 
Fatigue (Weimus, mean±SD) 19,6±16,3 26,6±14,5 6,9±8,3 7,8±10,4 ,059 ,001 ,000 
a: p-values of independent samples t-test or Fisher's exact test (gender, education). 
EDSS: Expanded Disability Status Scale; CES-D = Center for Epidemiologic Studies Depression Scale; Weimus = Wuerzburger 
Erschoepfungsinventar bei MS. 
 
Neuropsychological Assessment 
IPS and memory functions were assessed in a single 1.5h lasting session. To account for the 
multiple facets that can contribute to the IPS deficit in MS (Costa et al., 2017), three tests 
were applied assessing responsiveness for visual stimuli, divided attention for visual and 
auditory stimuli, and the ability to shift the attentional focus (Zimmermann & Fimm, 2011) 
(Table 7). Five standardized and validated memory tests were applied to assess verbal and 
visual memory (Helmstaedter et al., 2001; Strauss et al., 2006; Sturm & Willmes, 1999; 
Wolfram et al., 1989) (Figure 4). Tests were performed in the following fixed order: AVLT 
(learning), ROCF (copy), alertness, divided attention, flexibility, AVLT (recall, recognition), 
ROCF (recall), DCS, VLT, and NVLT. 
Individual raw scores of patients and controls were converted to standard T-scores based on 
normative data of the corresponding test manuals correcting for age-, gender-, and 
education. To analyse correlations with MRI, patients’ cognitive data was further corrected 
by calculating a z-score for each test: z = (patient’s T-score - mean of the control group) / SD 
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of the control group. Impairment in each test was defined as a z-score < -1.5. Two or more 
impaired memory scores were considered to indicate MI. The z-scores of the tests 
constituting IPS were averaged into an IPS index score (IPS_z). 
For comparison with the literature, performance in the most frequently used test of IPS in 
MS, the SDMT (Scherer, Baum, Bauer, Göhler, & Miltenburger, 2004), was analyzed in 62 
patients (21 EMS, 41 LMS) who agreed to a follow-up assessment 4.25 years (Min = 3.75, 
Max = 5.0, SD = 0.23) after the original evaluation. 
Table 7. Neuropsychological tests used to evaluate IPS. 
Testa 
Cognitive 
domain of 
interest 
Concept Scores 
Alertness Responsiveness Reaction to a simple visual 
stimulus. 
reaction time 
Divided 
attention 
Divided 
attention 
Selective reaction to competing 
auditory and visual stimuli 
reaction time auditory; 
reaction time visual; errors; 
omissions 
Flexibility Shifting 
attention 
mental flexibility 
"Set-shifting" task that requires 
reactions to complementary 
visual target stimuli on an 
alternate basis from trial to 
trial 
reaction time; errors 
a: Test are part of a computerized test battery(Zimmermann & Fimm, 2011).  
IPS: Information-processing speed.  
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Figure 4. Schematic illustration of the five different memory test paradigms used.  
Note: the displayed stimuli above resemble the original test material. Auditory Verbal Learning Test (AVLT): A list of 15 
unrelated words is read aloud five times to the patient at the rate of one item per second. After each reading, patients are 
asked to recall all words they can remember in any order. The sum of correct answers is the learning index. After an 
interference trial with 15 other unrelated words, patients are asked to recall the first list again. Delayed recall (number of 
correct items) and recognition (differences of correct answers and false positives) of the first list is tested after a period of 
20-25 minutes. Verbal Learning Test (VLT): In this recurring recognition test patients are presented 120 consecutive cards 
containing non-words at a rate of one card per 3 seconds. Eight of the first 20 non-words reappear in the course of the test, 
five times each. Patients are asked to memorize items and decide for each item if they recognize it from one of the previous 
cards or not. The difference between correct answers and false positives is scored as the learning index. Rey-Osterrieth-
Complex-Figure-Test (ROCF): Patients are asked to copy a complex figure on an empty sheet. After a 20-25 minutes delay, 
patients are asked to reproduce the figure again from memory. There is no warning of the memory component at any 
point. Accuracy of reproduction is scored based on the Taylor Scoring System. Nonverbal Learning Test (NVLT): Designed as 
a parallel test to the VLT, the stimulus material consists of geometric and irregularly shaped figures instead of non-words. 
All other parts of the test are identical to the VLT. Diagnosticum For Cerebral Damage (DCS): Nine geometric figures are 
presented at a rate of 10 seconds per item. Patients are asked to memorize the exact spatial arrangement of each figure 
and the order they were presented at. After each presentation patients are asked to reconstruct as many items as possible 
in the correct order using five wooden sticks of equal length. Two more trials are followed with a slightly faster presentation 
time of 5 seconds per item. Scoring is based on errors, i.e., a correctly reconstructed item (shape and position) is scored 
zero error points; a missed or entirely incorrect item is scored seven points. Incomplete reproductions are scored one error 
point for each incorrectly placed stick and for incorrect orientation (twisted, mirrored); incorrect positioning is scored two 
error points. The retention index is an indicator of immediate memory and defined as the sum of errors in the first trial. The 
learning index is defined as: (errors trial 1 –errors trial 3) / (errors trial1 x 3) x 100. 
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Magnetic resonance imaging (MRI) 
For standardization, all scans were audited with phantom and pilot subject scans on all sites 
at the beginning of the study. The MR parameters of the used sequences were optimized to 
get comparable T1- and T2-contrasts with the different scanners. Fourteen days before or 
after the neuropsychological assessment MRI data were acquired using one of the following 
systems: GE Sigma Horizon LX 1.5T neuro-optimized magnetic resonance system, Philips 
Intera 1,5T Master Nova, Siemens 1.5T Symphony, Siemens Avanto 1.5T neuro imaging 
magnetic resonance system, 3T Siemens Magnetom Vario scanner.  
The MR protocol consisted of a T1-weighted sagittal 3D scan with a voxel size of 1.0 mm3 to 
1.5 mm3. The proton density and T2-weighted scans were acquired as 3 mm axial slices 
aligned to the AC-PC line without a gap (TE = 12-30/90-120 ms, TR = 2800-4500 ms). In 
addition the MR protocol included a T1-weighted spin echo scan (TE < 25 ms, TR = 400-650 
ms) after injection of gadolinium-DTPA (0.3 mmol/kg) in the same orientation as the T2 scan.  
MRI was evaluated by independent and blinded technical staff members of the 
neuroimaging and neuroimmunology research group Magdeburg to obtain T1 lesion volume, 
T2 lesion volume, normalized hippocampus volume (NHV), normalized whole brain volume 
(NBV), and cortical thickness. The segmentation of lesions was performed on T1-weighted 
images with and without contrast agent and also on T2-weighted images using the 
DispImage package (Plummer, 1992). The volume of the stored region files were analyzed by 
using a calcroi tool. The contours of the hippocampus were traced on coronar slices using 
the software “MultiTracer” (Woods, 2003) following standardized guidelines (Pruessner et 
al., 2000) and stored as contour files in the ucf file format. Subsequently, the normalized 
hippocampus volumes were calculated with a self written matlab script using the ucf files 
and the head-normalization factor derived from SIENAX (Smith et al., 2002). The estimation 
of the total brain tissue volume from a single image and normalised skull size was performed 
using the software SIENAX (Smith et al., 2002) as part of FSL (Smith et al., 2004). Cortical 
reconstruction and volumetric segmentation was performed with Freesurfer 5.3 using recon-
all for all subjects. Detailed descriptions of the methods are given elsewhere (Dale, Fischl, & 
Sereno, 1999; Fischl, Sereno, & Dale, 1999). 
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Statistical Analysis 
Statistical analyses were performed with SPSS and by an independent biometrical institute 
using Statistical Analysis Systems (SAS 9.2). All analyses were restricted to subjects with 
complete data on all variables required for a particular analysis.  
Group differences for demographic and clinical variables were tested by independent 
samples t-test or Fisher’s exact test.  
Group differences for IPS and memory were tested by using independent samples t-test. To 
control for the effect of IPS on memory performance, a multivariate GLM was computed 
including IPS_z as a covariate. 
The SDMT performance was analyzed in each group separately. Additionally to the 
descriptive statistics, possible correlations to the IPS_z score at baseline were evaluated. 
Group differences for MRI variables were assessed using independent samples t-test, or, if 
variables were not normally distributed (verified using the Kolmogorov–Smirnov Test), 
Mann-Whitney test. 
Those memory scores that were found to be significantly lowered in patients compared to 
controls were further analysed in respect to correlations with the MRI data. First, partial 
correlations were computed with age and sex as covariates. Then, the relative contribution 
of MRI variables and IPS to the outcomes of the respective memory scores were analyzed by 
using stepwise regression analyses with the MRI parameters (values of T1/T2 lesion volumes 
were log-transformed in order to obtain a normal distribution) and IPS_z, as well as age, sex, 
depression and fatigue as predictor variables. As MRI variables were correlated, 
multicollinearity was checked with the tolerance factor (critical value of 0.2). The minimum 
significance level for entry and for staying in the equation was 0.05 and p = .1 to exit. A p-
value < 0.05 was considered statistically significant. 
3.3. Results 
Three patients and two control subjects that were screened for inclusion were not included 
because of severe fatigue or depression scores. In total, 25 sets of matched patients (i.e., 1 
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EMS and 2 LMS) were recruited. 16 of these sets were recruited entirely by one site, another 
5 sets were partially recruited by one site (i.e., 1 EMS and 1 LMS), and the remaining 4 sets 
were matched across three different sites (Figure 5). One patient withdrew his consent to 
participate after the MRI assessment (reasons unknown) and therefore no cognitive data 
was acquired. One patient could not perform three tests (divided attention, ROCF, DCS) 
because of severe spasms. Mental overload was the reason for one patient to not perform 
the tests of divided attention and NVLT and for another patient to dismiss auditory stimuli in 
the divided attention test. Data from the Flexibility test was missing for three patients and 
four control subjects because the incorrect test condition was applied. The baseline variables 
of the 152 included (Table 6) subjects show that matching for age at disease onset, 
education and gender was successful. EMS patients were younger and less disabled than 
LMS patients. Patients had higher depression and fatigue scores compared to controls. 
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Figure 5. Recruitment and matching of the 77 included MS-patients. 
Each box illustrates 1 of the 25 sets of 3 matched patients: One patient with early MS (EMS) was matched with 2 patients 
with late MS (LMS) in respect to sex, age at disease onset and education (the top row of each box indicates the 
corresponding matching criterion). The middle row illustrates at which site each patient was recruited and the local serial 
number (HAL = Halle, MAG = Magdeburg, ROS = Rostock, TEU = Teupitz, WER = Wermsdorf). The bottom row contains the 
actual inclusion dates. a = “MAG 07” was recruited as replacement for “MAG 04” who did not attend the first appointment, 
but was assessed later on; b = “MAG 10” withdrew her consent to participate in the study after the MRI and was replaced 
with “WER 17”. 
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Neuropsychological performance 
LMS 
LMS patients performed significantly lower than controls in all aspects of IPS (Table 8). They 
were found to have a declined responsiveness, an increased number of missed stimuli under 
divided attention, as well as a slowed reaction time and increased number of errors in the 
test of mental flexibility. 
The average impairment rate across all memory scores was 23 % (SD = 6) (minimum: 16 % in 
AVLT-learning; maximum: 34 % on DCS-learning; Figure 6). 43 % of LMS patients met the 
criterion for MI compared to 12 % in the control group (p < .001). Significant group effects 
were evident in the VLT, delayed recall of the AVLT, delayed recall of the ROCF, DCS-learning 
and NVLT (Table 8). However, IPS_z was found to be correlated with performances in the 
AVLT, ROCF, and DCS (Table 9). After controlling for IPS_z, only the difference in the VLT 
remained to be significant (Table 8). 
The average number of correct answers in the SDMT at follow-up was 46.58 (SD=13.0) which 
was below the norm (MT-values = 44.36, SD = 12.5, Min = 16, Max = 69). SDMT and IPS_z were 
found to be strongly correlated (r = .724, p < .001). 
EMS 
In contrast, only 12 % of EMS patients met the criterion for MI which was within the normal 
range (cEMS: 16 % MI, p = 1). The average impairment rate across all memory scores was 10 
% (SD = 7) and also did not exceed the one of the control group (10 %, SD = 5). Group effects 
were found in the VLT (EMS < cEMS) and AVLT-recognition (EMS > cEMS). Adding IPS as a 
covariate did not change the results (Table 8). 
The average number of correct answers in the SDMT at follow-up was 60.65 (SD = 7.4), 
which was slightly above the norm (MT-values = 52.26, SD = 7.3, Min = 38.5, Max = 68). No 
significant correlation was found between SDMT and IPS_z (r = .22, p = .350). 
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Figure 6. Impairment across different memory tests in patients with early and late MS.  
Cut-off for impairment was a standardized performance (according to the corresponding test manual) that fell 1.5 SD below 
the average of the individually matched control group. Early MS = MS Patients with disease duration < 2 years. Late MS = 
MS Patients with disease duration > 12 years.  AVLT = Auditory Verbal Learning Test. ROCF = Rey-Osterrieth-Complex-Figure. 
DCS = Diagnosticum For Cerebral Damage. VLT = Verbal Learning Test. NVLT = Nonverbal Learning Test. 
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Table 8. Results of neuropsychological assessment in MS patients with a short versus long disease 
duration, and matched controls. 
Neuropsychological Outcome Early MS Late MS 
patients (I) controls (II) p-value patients (III) controls (IV) p-value 
Test Score N T-value
a
 N T-value
a
 T-
Test
b
 
GLM with 
IPS as 
covariate
c
 
N T-value
a
 N T-value
a
 T-
Test
b
 
GLM with 
IPS as 
covariate
c
 
Information-processing speed 
Responsive- 
ness 
RT 25 47,4±9,0 25 46,9±6,2 ,826  51 42,7±10,0 50 47,4±7,5 ,009  
Divided 
attention 
vis. RT 25 51,0±6,2 25 51,2±6,4 ,911  49 45,9±10,2 50 51,1±7,8 ,005  
aud. RT 25 45,7±10,9 25 45,8±7,5 ,976  48 41,0±9,7 50 46,9±8,6 ,002  
errors 25 48,8±5,6 25 46,1±8,3 ,193  49 44,3±9,8 50 45,6±9,7 ,524  
omissions 25 51,6±5,4 25 48,7±6,8 ,096  49 43,7±10,9 50 48,5±8,5 ,017  
Flexibility RT 23 54,8±8,4 25 53,3±7,6 ,507  50 48,3±11,0 46 55,5±6,5 ,000  
errors 23 55,5±6,0 25 55,4±6,4 ,964  50 50,8±10,6 46 57,3±5,9 ,000  
Verbal memory 
AVLT learning 25 55,1±8,8 25 55,0±8,5 ,974 ,862 51 53,4±8,9 50 55,8±8,3 ,169 ,864 
 del. recall 25 52,2±8,3 25 54,5±9,8 ,379 ,393 51 48,0±8,6 50 52,8±7,4 ,003 ,151 
 recognition 25 52,1±2,2 25 50,3±3,5 ,042 ,049 51 49,4±6,5 50 51,7±5,7 ,056 ,220 
VLT learning 25 45,7±8,7 25 51,0±7,5 ,026 ,035 51 44,4±10,5 50 49,5±9,9 ,014 ,028 
Visual memory 
ROCF del. recall 25 54,1±6,6 25 53,0±7,6 ,580 ,695 50 51,0±8,4 50 54,7±5,5 ,012 ,419 
DCS retention 25 51,6±8,9 25 50,8±8,5 ,746 ,767 50 48,5±11,9 50 50,7±7,2 ,266 ,627 
 learning 25 42,8±11,0 25 47,2±10,1 ,147 ,171 50 37,9±14,4 50 44,7±11,6 ,011 ,514 
NVLT learning 25 44,3±10,7 25 45,5±10,1 ,676 ,679 50 41,7±10,2 50 45,9±8,5 ,027 ,121 
a: standardized T-values (mean±SD; corrected based on norms of the corresponding test manual). b: independent samples T-test; c: Multivariate Analysis of 
Variance including the averaged performance in tests of information-processing speed as a covariate. 
IPS = Information-processing speed; AVLT = Auditory Verbal Learning Test; ROCF = Rey-Osterrieth-Complex-Figure; DCS = Diagnosticum For Cerebral Damage; VLT 
= Verbal Learning Test; NVLT = Nonverbal Learning Test; del. recall = delayed recall; RT = reaction time; Vis. RT = reaction time for visual stimuli; Aud. RT = 
reaction time for auditory stimuli. 
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Table 9. Correlations between memory, MRI, and IPS. 
  
IPS NBV Corti. 
thickn.  
NHV  
left 
NHV  
right 
T1LV T2LV 
early MS (< 2 years of MS) 
VLT learning -,03 -,14 -,09 -,01 ,00 -,27 -,23 
late MS (> 12 years of MS) 
AVLT del. recall ,51*** ,10 ,24 ,53*** ,42** -,01 -,05 
VLT learning -,06 ,09 ,27† ,30* ,05 -,10 -,06 
ROCF del. recall ,40** ,11 ,13 ,25† ,29* ,06 ,06 
DCS learning ,50*** ,21 ,38** ,29† ,26† -,07 ,01 
NVLT learning ,09 ,14 ,32* ,29† -,02 -,20 -,10 
Only those memory tests were evaluated that were found to be significantly lowered in patients compared to controls.  
Correlations corrected for age and sex; †: p<.10; *: p<0.05; **: p<0.01; ***: p<0.001. 
IPS = Information-processing speed; NBV = normalized brain volume; Corti. Thickn. = Cortical thickness; NHV = normalized hippocampal 
volume; T1LV = log-transformed T1 lesion volume; T2LV = log-transformed T2 lesion volume; AVLT = Auditory Verbal Learning Test; ROCF = 
Rey-Osterrieth-Complex-Figure; DCS = Diagnosticum For Cerebral Damage; VLT = Verbal Learning Test; NVLT = Nonverbal Learning Test. 
 
MRI 
The group means show that all parameters were significantly different between EMS and 
LMS (Table 10). 
Table 10. Results of MRI in MS-patients with a short versus long disease duration. 
  Early MSa Late MSb pc 
N 25 50   
Median NBV, cm³ [min-max] 1567 [1459-1721] 1452 [1154-1669] ,000 
Median Cortical thickness, mm [min-max] 2,41 [1,88-2,57] 2,30 [1,85-2,54] ,002 
Mean NHV left, cm³ (SD) 2,66 (0,45) 2,39 (0,38) ,006 
Mean NHV right, cm³ (SD) 2,63 (0,43) 2,43 (0,41) ,043 
Median T1LV, cm³ [min-max] 1,39 [0,34-10,19] 4,54 [0,35-29,03] ,000 
Median T2LV, cm³ [min-max] 4,20 [0,73-19,49] 13,18 [2,27-57,37] ,000 
a: disease duration < 2 years, b: disease duration > 12 years; c: Mann-Whitney Test or t-Test;  
NBV = normalized brain volume; NHV = normalized hippocampal volume; T1LV = T1 lesion volume; T2LV = T2 lesion volume. 
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LMS 
Left and right NHV were correlated with verbal memory tests, whereas cortical thickness 
was correlated with two tests for visual memory (Table 9). NBV (r = .33), NHV left (r = .37), 
NHV right (r = .30, all p < .05), and cortical thickness (r = .28, p < .10) were also correlated 
with IPS_z. 
The regression analyses (Figure 7) revealed that IPS_z was the strongest predictor for 
performance in the AVLT, ROCF, and DCS, explaining between 17 % and 28 % of the variance. 
Sex and left NHV were significant predictors for performance in both verbal memory scores 
(i.e., VLT, AVLT), explaining between 7 % and 17 % variance. Cortical thickness was the only 
predictor for performance in the NVLT. 
3.2.2 EMS 
In EMS, correlations between memory, IPS and MRI were only evaluated for performance in 
the VLT and did not reveal any significance (Table 9, Figure 7). 
 
 
Figure 7. Stepwise regression analyzes of impaired memory performance in patients with an early or a late disease stage.  
Regression models included normalized brain volume (NBV), normalized hippocampus volume left (NHV left), normalized 
hippocampus volume right (NHV right), cortical thickness (Corti. Thickn.), as well as age, sex, depression, and fatigue as 
possible predictors. The minimum significance level for entry and for staying in the equation was 0.05 and p=.1 to exit. IPS = 
Information-processing speed; AVLT = Auditory Verbal Learning Test; ROCF = Rey-Osterrieth-Complex-Figure; DCS = 
Diagnosticum For Cerebral Damage; VLT = Verbal Learning Test; NVLT = Nonverbal Learning Test. 
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0.290** 0.08
IPS
std. β 
0.413**
DCS - learning
F(1, 47) = 18.81, p<.001, adj.  R²=0.275
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3.4. Discussion 
Previous studies on MI in MS were conflicting in respect to possible early manifestations of 
MI and to the role hippocampal damage might play. Three methodological details that 
possibly contributed to these inconsistencies were accounted for in the present investigation 
of MI: disease stage, memory assessment, and slowed IPS. We found significant MI across 
different assessment paradigms in the LMS group, whereas the EMS group appeared to be 
cognitively preserved. Slowed IPS was found to be the most robust predictor for impairment 
in memory, followed by left-sided hippocampal atrophy for verbal and cortical thinning for 
visual memory. 
Our findings both confirm and extend the results from previous studies that found MI as a 
prevalent symptom of MS. The rate of 43% MI in LMS corresponds well with prior data 
(Planche et al., 2015; Vanotti, Benedict, Acion, & Cáceres, 2009), although the effect sizes 
suggest a slightly lower severity of MI in our sample (Thornton & Raz, 1997). A distinctive 
feature of the present study was the use of several different test paradigms. We found 
elevated impairment rates in each test suggesting that MI in MS is detectable independently 
of learning material (verbal, visual), encoding (incidental, intentional), and retrieval (free 
recall, recognition, recurring recognition). This indicates a more global pattern of MI which 
corresponds with findings from two meta-analyses of MI in MS (Prakash et al., 2008; 
Thornton & Raz, 1997). 
In contrast, we found no evidence for such a global effect on memory functioning in EMS, 
and also no support for the idea of a differential pattern of MI in EMS. Instead, our sample 
appeared to be unaffected by MI across several sensitive and validated memory test 
paradigms. This suggests that the type of memory assessment may not be the reason for 
conflicting findings of impaired (Grant et al., 1984; Potagas et al., 2008; Schulz et al., 2006; 
Sicotte et al., 2008) versus well preserved memory functions in EMS (Kern et al., 2015; 
Nygaard et al., 2015). 
However, it has to be questioned whether the EMS sample was representative. On one 
hand, a selection bias in respect to cognitive functioning seems unlikely because the 
recruitment was performed consecutively at all sites and biased only by the search for 
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matching patients. On the other hand, a sample of 25 patients always carries the risk of 
being non-representative by chance in respect to relevant sample characteristics such as 
length of the infra-clinical course, age, sex, education, physical disability, depression and 
fatigue (Prakash et al., 2008). The present sample of EMS can be considered representative 
in respect to age (i.e., 29 years), sex (32% males), disease duration (1 year), and level of 
education (Krings, 2011), but not in respect to depression and fatigue (severe cases 
excluded; CES-D=13). Also, the length of the infra-clinical course remains unknown. Higher 
rates of MI have been found in samples of EMS that were characterized by older ages (e.g., 
37-42 years (Amato, Portaccio, Goretti, Zipoli, Iudice, et al., 2010; Grant et al., 1984; Schulz 
et al., 2006; Sicotte et al., 2008)), elevated levels of depression (e.g., CES-D=33 (Glanz et al., 
2007)), or higher rates of male patients (e.g., 46% males (Potagas et al., 2008)). It has to be 
noted though that the present study was not designed to draw conclusions on the MI 
prevalence in EMS. Thus, the results only suggest that the findings of well-preserved 
memory functions in small EMS samples (Brissart et al., 2013) may not be due to an 
incomprehensive memory assessment. 
An important finding of the present study is the association between slowed IPS and MI in 
LMS. This correlation was evident in tests assessing visual and verbal memory using the 
same paradigm that all standard screening tests for MI in MS are based on (i.e., learning over 
trials) (Langdon et al., 2012). This corresponds well with investigations of working memory in 
MS that also revealed large contributions of IPS to impairment (Leavitt, Lengenfelder, 
Moore, Chiaravalloti, & DeLuca, 2011). A global factor of decreased cognitive processing 
efficiency has also been found in the validation study of the MACFIMS battery involving IPS, 
executive functions, working memory, and visual memory (Benedict, Cookfair, et al., 2006). 
Recently, Sacco et al. speculated about a global processing efficiency factor as well, after 
finding that nearly all of the patients in their study suffered from slowed IPS although they 
were strictly selected for MI (Sacco et al., 2015). 
Another important finding of the present study is that IPS deficits were not only associated 
with MI but also with hippocampal atrophy. The same has been found using the SDMT 
(Debernard et al., 2015; Koenig et al., 2014) and the PASAT (Longoni et al., 2015) as a 
screening test for IPS deficits. In fact, it is a common finding that atrophy in different areas 
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(e.g., hippocampus, thalamus, caudate) are correlated with cognitive impairment 
simultaneously (Daams et al., 2015; Damjanovic et al., 2017; Pinter et al., 2015), possibly due 
to shared variance (Longoni et al., 2015). Therefore, the present correlation between 
hippocampal atrophy and IPS may be explained by the effect of unspecific tissue loss on 
cognitive functioning. According to recent models, diffuse cerebral damage could lead to 
cognitive inefficiency in MS by disconnecting broader cognitive networks (P. Calabrese & 
Penner, 2007; Dineen et al., 2009; Rocca et al., 2015; Schoonheim et al., 2015). 
Thus, our study suggests that slowed IPS could be a mediator that needs to be accounted for 
in correlation analyses of MRI and MI. In the present study, such an analysis revealed that 
additionally to key contributions of IPS, structural MRI parameters remained as relevant 
predictors for MI in MS (Kiy et al., 2011; Planche et al., 2015; Sacco et al., 2015; Sicotte et al., 
2008). However, a hippocampal contribution was only evident in verbal MI (Koenig et al., 
2014; Pardini et al., 2014) and our data implies that one reason for this and similar findings 
(Anderson et al., 2010; Damjanovic et al., 2017; Sacco et al., 2015) might be a more 
dominant involvement of cortical damage in visual MI. This could explain why visual but not 
verbal memory deficits have been found to be associated with impairment in working 
memory, executive functions and IPS (Benedict, Cookfair, et al., 2006). 
Several limitations have to be considered regarding this study. First and foremost, 
interpretation of the results in the EMS group is limited by its small sample size. The so 
achieved statistical power was not sufficient to reveal significance of smaller effects on MI. 
Thus, preclinical disturbances in the AVLT delayed recall, NVLT and DCS learning cannot be 
excluded. The sample size also precludes valid conclusions on the prevalence of MI in EMS 
and especially a comparison to the larger LMS group. A direct comparison of the correlations 
between EMS and LMS is also not feasible because of the differences in sample size and MI 
incidence. Secondly, the findings in LMS cannot be generalized onto groups that were not 
included in the present study, i.e. groups with intermediate disease durations (2 to 12 years), 
severe disability (median EDSS > 3.3), or PPMS. These groups may be characterized by a 
specific pattern of MI that is less confounded with IPS. Moreover, possible correlations to 
focal cortical thinning were not evaluated. Thirdly, the use of different MRI scanners in a 
multicentre study can be source of error. However, the standardization of image acquisition 
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and analysis in the present study was adequate to obtain reliable data (Damjanovic et al., 
2017), and moreover, patients were distributed unsystematically across sites which 
minimizes systematic errors. Lastly, a possible mediating role of working memory 
impairment between IPS and memory deficits cannot be excluded because it was not 
assessed.  
In conclusion, this study suggests that later stages of MS are characterized by unspecific 
memory deficits that relate to a generally decreased information-processing efficiency as 
well as to tissue loss in the left hippocampus and the cortex. Future studies should include 
IPS as a covariate for MI. 
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4. Study three: A smart peek: Visual processing 
parameters in early vs. late MS refer to cognitive 
ability. 
4.1. Introduction 
Cognitive impairment (CI) can affect patients with multiple sclerosis (MS) from the beginning 
and is regarded as an important predictor of disease course and functional outcome 
(Deloire, Ruet, Hamel, Bonnet, & Brochet, 2010; Langdon, 2011). Therefore, the 
identification of subjects at risk for cognitive decline is considered as a main task for current 
research (Rocca et al., 2015), and finding assessment instruments for early detection of 
cognitive impairment as an urgent requirement. 
A large part of MS-related CI can be accounted for by a general processing efficiency factor, 
as it is reflected by measures of processing speed like the symbol digit modalities test (Costa 
et al., 2017). One influential perspective on general cognitive effectiveness, which is mainly 
invoked by intelligence research, posits that it has a close association with the capability to 
extract information from rapid visual displays (Deary, Der, & Ford, 2001; Luck & Vogel, 2013; 
Tachibana, Namba, & Noguchi, 2014). In the present paper, we adopt such a perspective 
based on a mathematically formalized theory, the “theory of visual attention” (TVA) 
(Bundesen, 1990). TVA can be used to separate visual processing capacity into four distinct 
components from performance in a simple psychophysical task (Foerster et al., 2016). This 
TVA-based assessment has been successfully applied to patients with different neurological 
disorders in over 30 clinical studies (Habekost, 2015) and was recently found to be sensitive 
to MS-related cognitive fatigue (Kluckow et al., 2016). We investigated its potential to detect 
abnormalities in MS, and to function as a possible index of CI. 
TVA-based whole report was applied to 2 groups of MS-patients, one at a very early, one at a 
later disease stage. We asked which of the TVA-based components of visual processing 
capacity are already impaired at an early stage, and how the pattern differs from the late 
stage. Finally, we assessed how TVA-based parameters of visual processing capacity relate to 
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disease progression and the patients’ cognitive status as measured by a neuropsychological 
test battery targeting key areas of CI. 
4.2. Methods 
The present paper reports results of a multi-center, cross-sectional study that was designed 
to compare visual processing capacity, cognitive functions and associated MRI markers in 
early and late MS. Since first signs of CI can occur very early in MS and later deterioration 
results from longer time periods (Amato et al., 2001), the study included patients with 
disease durations of either less than 2 years or more than 12 years. To control for possible 
confounders, patients were recruited as individual pairs matched for age at disease onset, 
sex, and education. 
The study was approved by the local Ethical Committees. All participants provided written 
informed consent prior to participation. 
Subjects 
77 patients with a first clinical demyelinating event related to MS or a deﬁnite MS (Polman 
et al., 2005) were recruited from 5 MS-centers in Germany (Wermsdorf, Halle, Magdeburg, 
Rostock, Teupitz) between February and September 2011. Exclusion criteria were a relapse 
or corticosteroid treatment 4 weeks prior to neuropsychological assessment, visual acuity 
<0.2, severe fatigue (i.e., Weimus ≥ 52; (Flachenecker et al., 2006)) or depression (i.e., CES-D 
≥ 39; (Hautzinger & Bailer, 1993)), alcohol abuse, pregnancy, and other relevant serious 
neurological and internal medical diseases as well as exclusion criteria for MRI. A sex ratio of 
1 : 2-3 (m : f) was aimed at. Patients were assigned to 2 groups, one group having a disease 
duration of <2 years from the first clinical event (early MS, EMS, N = 25) and the other group 
a disease duration >12 years (late MS, LMS, N = 52). Patients were individually matched with 
respect to age at disease onset (±3 years), sex and education, i.e., two matching LMS-
patients were recruited after inclusion of one EMS-patient. More LMS-patients were 
recruited to account for the higher variety of structural and cognitive changes at later 
disease stages. 
  
Page | 62  
The performance of MS-patients in the TVA-based whole report procedure (described 
below) was compared to that of control subjects taken from a panel of healthy subjects who 
have been assessed during the course of our TVA-based studies under standardized 
conditions. Based on these existing data, 2 control groups, i.e., cEMS and cLMS were formed 
separately for each patient group, matched for age, sex, and education. 
TVA-based assessment of visual processing capacity 
Visual processing capacity was assessed by using a simple psychophysical task, the whole 
report of brief letter arrays in combination with a TVA-based modeling of the individual test 
performance. This procedure has been employed in several previous studies and a detailed 
description can be found there (Bublak et al., 2011). The task lasted approximately 30 
minutes and included a pre-test period comprising 24 trials, followed by 192 experimental 
trials (Figure 8). Four independent parameters were computed that constitute visual 
processing capacity: the minimum time where conscious visual processing starts (perceptual 
threshold, t0); the number of visual objects that can be processed per second (processing 
rate, C); the number of visual objects that can be maintained in parallel within visual short-
term memory (VSTM storage capacity, K); the additional time a visual percept is available for 
processing due to visual persistence (iconic memory buffering, μ). Congruent testing 
conditions and procedures were assured by intensive training of examiners before the 
project started. 
Exposure durations were determined for each subject individually in a pre-test phase to 
adjust for differences in baseline performance between subjects. This way, the data 
gathered in the main test would allow optimal modeling of each subject’s individual growth 
function of visual information uptake by excluding extreme exposure durations (i.e., 
durations below the threshold of conscious perception or durations beyond ceiling 
performance). For this purpose, the whole report was applied with masked displays and a 
fixed exposure duration. The criterion was an average of one correctly reported letter per 
trial (i.e. 20% report accuracy) in a series of 24 masked trials (12 for each hemi-field). The 
exposure duration determined during the pre-test was then used as the intermediate 
exposure duration in the experimental session, together with a shorter (half as long) and a 
longer (twice as long), exposure duration. 
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Figure 8. TVA-based assessment of visual processing capacity.  
(Left): At each trial, five random letters appeared either on the left or right side of the fixation cross. The exposure duration 
of the letter array was chosen from 3 predetermined lengths (i.e., short, intermediate, long). Thereafter, either a blank 
screen or a screen containing masks for each letter was displayed. Side of presentation, exposure duration and masking 
were randomly chosen. Subjects were asked to verbally report all letters they had identified and could report them in any 
order and with no emphasis on speed of report. The experimenter recorded the reported letter(s) and initiated the next 
trial after the subject had indicated that he/she was ready. (Right): Performance was evaluated as the mean number of 
correctly reported letters at 6 different ‘effective’ exposure durations (i.e., 3 exposure durations * 2 masking conditions). 
This data was used to model an exponential growth function according to a maximum likelihood method. The resulting 
curve was characterized by the three parameters reflecting visual processing capacity: The slope at the curves’ origin 
determines the processing rate C, the asymptote determines visual short-term-memory storage capacity (K); the origin 
determines the perceptual threshold (t0). Additionally, the performance difference between unmasked and masked trials 
determines iconic memory buffering (μ). 
 
Neuropsychological assessment 
Conventional neuropsychological assessment was performed on a separate day, 2 weeks 
before or after the TVA-based assessment. A comprehensive test battery was administered 
in a single 1.5-hour session to assess different aspects of information-processing speed,  
verbal memory, visual memory, and visuo-constructive abilities (Table 11). Composite scores 
were computed by averaging the z-normalized results of the corresponding tests after 
correction for age, sex and education (based on normative data of the test manuals and 
results from an individually matched control group (Köhler et al., 2017). Additionally, results 
of the symbol digit modalities test (SDMT), a widely accepted standard instrument for 
assessing cognition in MS patients (Benedict et al., 2017; Van Schependom et al., 2014), 
were also obtained from 56 patients (20 EMS, 36 LMS) who agreed to a follow-up 
assessment (this follow-up assessment was performed 4.25 years (Min = 3.75, Max = 5.0, SD 
= 0.24) after the initial evaluation). 
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Table 11. Cognitive assessment battery. 
Domain Testa Concept 
Information-
processing 
speed 
Alertness Response time to a simple visual stimulus appearing after an 
auditory cue or no cue 
Divided 
attention 
Response time to auditory and visual stimuli presented in parallel 
Flexibility Response time to complementary visual target stimuli in an 
alternating manner in a "set-shifting" task 
SDMT Substitution task in which nine numbers have to be paired with 
abstract symbols as rapidly as possible according to a provided key 
Visuo-
constructive 
abilities 
ROCF Copying a complex figure graphically. 
Verbal 
memory 
AVLT Learning a list of orally presented nouns with immediate and 
delayed retrieval 
VLT Recurring recognition test of non-words 
Visual 
memory 
ROCF Delayed free reproduction of a previously copied figure (memory 
component was unannounced) 
DCS Learning nine different geometric figures and the order they are 
presented at over the course of three trials 
NVLT Recurring recognition test of geometric and irregularly shaped 
figures 
a: Tests were performed in the following fixed order: AVLT (learning), ROCF (copy), alertness, divided attention, flexibility, AVLT (recall, 
recognition), ROCF (recall), DCS, VLT, and NVLT. The SDMT was applied at a follow-up assessment 4.25 years after the original evaluation 
for comparison with the literature. 
SDMT = Symbol Digit Modalities Test; ROCF = Rey-Osterrieth Complex Figure Test; AVLT = Rey Auditory Verbal Learning Test; VLT = Verbal 
Learning Test; DCS = Diagnosticum fuer Cerebralschaedigung; NVLT = Nonverbal Learning Test. 
 
Statistical analyses 
Statistical analyses were performed with SPSS and applied to complete datasets only.  
Group differences of the TVA-based parameters were evaluated by using independent 
samples t-test after verifying normal distribution (one-sample Kolmogorov-Smirnov Test). 
Associations to clinical and demographic variables were evaluated by using Spearman's rank 
correlation (age, EDSS, disease duration, depressive mood, fatigue) or independent samples 
t-test (sex, education, history of optic neuritis). Correlations between TVA parameters and 
conventional neuropsychological performance were analyzed by using Pearson correlation. 
The relative contribution of TVA-based parameters to the neuropsychological outcomes was 
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analyzed by using stepwise regression analyses including clinical and demographic variables 
as predictor variables in block 1 and the TVA-based parameters in block 2. 
4.3. Results 
69 patients were included into the present analysis (Table 12). One patient withdrew his 
consent to participate, two patients had insufficient visual acuity to perform the TVA test, 
and five patients were excluded from the analysis because their TVA data was not recorded 
due to a software error. 
Table 12. Clinical and demographic variables. 
  
early stagea late stageb 
EMS cEMS LMS cLMS 
N 24 24 45 45 
Sex (male : female) 1 : 2.43 1 : 2.43 1 : 2.46 1 : 2.75 
Age (years) 
28.9 (6.7)  
[20-47] 
29.0 (7.1)  
[20-48] 
45.1 (7.9)  
[32-61]*** 
44.7 (8.5)  
[27-60] 
Education ≥12 years (N (%)) 9 (38%) 11 (46%) 11 (24%) 19 (42%) 
Age at disease onset (years) 
28.0 (7.0)  
[18-47] 
 
28.2 (6.8)  
[19-46] 
 
Disease duration (years) 
1.0 (0.8)  
[0-2]  
16.9 (5.4) 
 [10-37]  
EDSS (Median [min-max]) 1.8 [0-6] 
 
3.0 [0-8]** 
 History of optic neuritis (N (%)) 11 (46%) 
 
19 (42%) 
 
Depression (CES-D) 
13.0 (9.9)  
[1-36] 
 
13.1 (9.0)  
[0-34] 
 
Fatigue (Weimus) 
19.9 (16.6)  
[0-50] 
 
26.6 (14.6)  
[0-51] 
 Values are displayed as mean (SD) [min-max]. Group differences were tested by using Fisher's Exact Test (sex, education) or independent 
samples t-test (*: p<.05; **: p<.01; ***: p<.001). 
a: patients with a disease duration of < 2 years and matched controls. 
b: patients with a disease duration of  > 12 years and matched controls. 
EMS = early MS; LMS = late MS; cEMS = with EMS matched control group; cLMS = with LMS matched control group; EDSS = Expanded 
Disability Status Scale; CES-D = Center for Epidemiologic Studies Depression Scale; g: Weimus = Wuerzburger Erschoepfungsinventar bei MS. 
 
Visual processing capacity 
Processing rate C, visual short term memory capacity K, and iconic memory µ were 
significantly lowered in both MS groups compared to controls (Table 13). In contrast, the 
perceptual threshold t0 was only elevated in LMS, not in EMS. 
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A direct contrast of EMS and LMS revealed that the effects on parameters C and µ were 
more pronounced in LMS (both p < .05), whereas no additional effect was found with 
respect to K (p = .647). 
Table 13. TVA-based visual processing capacity in early and late stages of MS. 
 
MS control p 
early stage MS 
Perceptual threshold t0 (msec) 11.8 (12.8) 9.09 (16.3) .518 
Processing rate C (elements/sec) 20.66 (5.7) 26.12 (11.6) .045 
VSTM capacity K (number of elements) 2.59 (0.50) 3.41 (0.70) .000 
Iconic memory µ (msec) 102 (40.3) 142 (48.6) .003 
late stage MS 
Perceptual threshold t0 (msec) 46.8 (39.3) 24.8 (30.9) .004 
Processing rate C (elements/sec) 17.15 (5.9) 20.55 (8.1) .025 
VSTM capacity K (number of elements) 2.53 (0.51) 3.15 (0.61) .000 
Iconic memory µ (msec) 79 (45.3) 151 (58.0) .000 
Results are displayed as mean (SD). Group differences were tested by using independent samples t-test. 
TVA = Theory of visual attention; VSTM = visual short term memory. 
 
Associations with clinical and demographic variables 
The analyses revealed age as the only demographic variable that was significantly associated 
with visual processing capacity in both groups, affecting primarily perceptual threshold t0 
and to a lesser extent processing rate C (Table 14). In LMS, education was associated with t0 
as well. Sex, however, was not associated with any of the visual processing parameters in 
either group. 
With respect to the clinical variables, no associations with optic neuritis and disease duration 
were evident in either group (Table 14). However, in LMS a series of significant weak to 
moderate correlations between the perceptual threshold t0 and several clinical variables was 
apparent including EDSS, depressiveness, and fatigue (Table 14). This pattern was not 
evident in EMS and not resembled by the other three visual processing components (i.e., C, 
K, and µ).   
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Table 14. Associations between TVA-based visual processing capacity and clinical and 
demographic variables. 
 
t0 C K µ 
Early stage MS 
Age .460* -.219 -.024 .168 
Sex 
(female vs. male) 
13.6 (13) vs.  
7.6 (13) 
20.9 (6) vs.  
20.0 (6) 
2.5 (0.6) vs.  
2.8 (0.2) 
106 (39) vs.  
92 (45) 
Education  
(≥12y vs. <12y) 
10.7 (9) vs.  
12.6 (15) 
21.3 (6) vs.  
20.2 (6) 
2.4 (0.6) vs.  
2.7 (0.4) 
112 (37) vs.  
97 (42) 
EDSS -.037 .107 .013 -.018 
Disease duration (years) -.319 -.061 .181 .234 
Optic neuritisa  
(yes vs. no) 
13.5 (15) vs. 
10.5 (11) 
18.7 (4) vs.  
22.3 (7) 
2.7 (0.4) vs. 
2.5 (0.6) 
112 (50) vs. 
94 (29) 
Depression (CES-D) .043 .150 .122 -.057 
Fatigue (Weimus) .148 .037 .424* .053 
Late stage MS 
Age .357* -.333* .118 -.138 
Sex  
(female vs. male) 
42.0 (37) vs.  
58.4 (43) 
16.7 (6) vs.  
18.2 (6) 
2.5 (0.5) vs.  
2.5 (0.4) 
83 (47) vs.  
70 (40) 
Education  
(≥12y vs. <12y) 
22.8 (28) vs.  
54.5 (39)* 
18.1 (5) vs.  
16.9 (6) 
2.6 (0.5) vs.  
2.5 (0.5) 
94 (40) vs.  
74 (47) 
EDSS .454** -.200 .216 -.169 
Disease duration (years) .075 -.096 .162 -.051 
Optic neuritisa  
(yes vs. no) 
47.5 (39) vs.  
46.3 (40) 
16.7 (6) vs. 
17.5 (6) 
2.6 (0.6) vs. 
2.5 (0.5) 
84 (47) vs. 
76 (44) 
Depression (CES-D) .298* -.193 .142 .090 
Fatigue (Weimus) .328* -.151 .151 .084 
Associations with continuous variables were tested by using Spearman's rank correlation, those with dichotomous variables by comparing 
group means (SD) using independent-samples t-test (†: p<.10; *: p<.05; **: p<.01). 
a: Presence of optic neuritis in the patients’ clinical history.  
t0 = Perceptual threshold; C = Processing rate; K = Visual short-term memory capacity; µ = Iconic memory; EDSS = Expanded Disability Status 
Scale; CES-D = Center for Epidemiologic Studies Depression Scale; Weimus = Wuerzburger Erschoepfungsinventar bei MS. 
 
Association with neuropsychological assessment 
In the EMS group, cognitive functioning, as assessed by conventional neuropsychological 
tests, appeared to be widely preserved (Table 15). The largest deviations from the normative 
data were present in verbal and visual memory; however these did not reach statistical 
significance in this sample of 24 patients. Weak correlations between t0 and verbal memory, 
as well as between t0 and visual memory were found (Table 15). Another weak, but 
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statistically not significant (p = .13) correlation was indicated between the TVA-based 
processing rate C and measure of information-processing speed. 
In the LMS group, information-processing speed, verbal and visual memory were affected by 
MS (Table 15). A striking pattern of mostly moderate correlations between the perceptual 
threshold t0 and neuropsychological performance was evident across all evaluated cognitive 
domains (Table 15). As in the EMS group, C and information-processing speed were found to 
be weakly correlated as well. 
Table 15. Cognitive functioning in early and late MS and its correlation to visual processing 
capacity. 
  
Cognitive functioning 
a 
Correlation to visual processing b 
mean z (SD) t0 C K µ 
Early stage MS 
Information-processing speed 0.13 (0.6) -.167 .318 .101 -.048 
Visuo-constructive abilities -0.02 (1.1) -.153 .133 -.011 .206 
Verbal memory -0.11 (0.7) -.461* .122 .007 .244 
Visual memory -0.10 (0.7) -.356† .007 .156 .250 
Late stage MS 
Information-processing speed -0.59 (0.9)*** -.504** .310* .134 .108 
Visuo-constructive abilities 0.00 (1.2) -.661** .113 .059 .231 
Verbal memory -0.48 (0.9)* -.359* .053 -.181 -.066 
Visual memory -0.46 (1.0)* -.534** .227 -.003 .095 
a: Composite scores were computed by averaging the z-normalized results of the corresponding cognitive tests after correction for age, sex 
and education. Group effects between patients and individually matched controls were assessed by using the t-test. 
b: Pearson correlation coefficients. 
†: p<.10; *: p < .05 **: p < .01. 
t0 = Perceptual threshold; C = Processing rate; K = Visual short-term memory capacity; µ = Iconic memory. 
 
The regression analyses confirmed that in LMS, t0 was an independent predictor of 
information-processing speed, visual memory, and visuo-constructive abilities even after 
controlling for all clinical and demographic variables (Figure 9). In EMS, t0 remained to be a 
significant predictor (std. β = -0.580, p < .01) of verbal memory (F(2, 23) = 10.90, p<.001, adj.  
R² = 0.463) additionally to sex (std. β = -0.56, p < .01). 
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Figure 9. Stepwise regression analyses of cognitive performance in late stage MS. 
Regression models included age, sex, education, disease duration, EDSS, history of optic neuritis, depressiveness and 
fatigue in block 1 and the TVA-based parameters constituting visual processing capacity, i.e., perceptual threshold (t0), 
processing rate (C), visual short-term memory capacity (K), and iconic memory (µ) in block 2. The minimum significance 
level for entry and for staying in the equation was 0.05 and p=.1 to exit. 
 
The detailed analysis of information-processing speed in LMS showed that after correction 
for EDSS and age, respectively, t0 remained to be correlated with reaction time for visual and 
auditory stimuli in the test of divided attention, as well as to qualitative measures in the 
tests of divided attention and flexibility. C remained to be correlated with reaction time in 
the flexibility test after correction for age (Table 16). 
 
Table 16. Pearson correlations [corrected partial correlations] between different aspects of 
information-processing speed and visual processing capacity in late stage MS. 
  
  TVA-based parameters 
  t0 C K µ 
Alertness reaction time -.201† *.059] .303* [.237†] -.157 -.077 
Divided  
attention 
reaction time  
visual 
-.393** [-.297*] .218† [.208†] .232† .222† 
reaction time  
auditory 
-.387** [-.278*] .078 [.067] .312* .130 
errors -.355** [-.247†] .280* [.231†] -.161 -.052 
omissions -.296* [-.291*] .106 [.091] .130 .180 
Flexibility reaction time -.369** [-.245†] .285* [.262*] .134 .047 
errors -.359** [-.211†] .194 [.111] .082 .039 
SDMT (N=36) correct answers -.608** [-.466**] .312* [.252†] .177 .205 
Values represent correlation coefficients. Partial correlation reflect corrections for those clinical and demographic variables that were 
significantly correlated with TVA-based parameters (t0: controlled for age and EDSS; C: controlled for age). Correlations were tested one-
sided (†: p<.10; *: p < .05 **: p < .01.). 
 t0 = Perceptual threshold; C = Processing rate; K = Visual short-term memory capacity; µ = Iconic memory. 
 
Early stage MS
(n=24)
INFORMATION-PROCESSING SPEED
n.s.
VISUAL-SPATIAL CONSTRUCTIONAL ABILITY
n.s.
VERBAL MEMORY
F(2, 23) = 10.90, p<.001, adj.  R²=0.463
VISUAL MEMORY
n.s.
Sex
t0
std. β ΔR²
-0.558** 0.19
-0,580*** 0.32
Late stage MS
(n=45)
INFORMATION-PROCESSING SPEED
F(2, 43) = 9.59, p<.001, adj.  R²=0.285
VISUAL-SPATIAL CONSTRUCTIONAL ABILITY
F(2, 43) = 15.88, p<.001, adj.  R²=0.409
EDSS
t0
std. β ΔR²
-0.292† 0.22
-0.361* 0.10
EDSS
t0
std. β ΔR²
0.004 0.10
-0.663*** 0.34
VERBAL MEMORY
F(2, 43) = 5.66, p<.01, adj.  R²=0.178
VISUAL MEMORY
F(2, 43) = 8.89, p<.001, adj.  R²=0.268
Sex
EDSS
std. β ΔR²
-0.303* 0.13
-0.297* 0.09
Fatigue
t0
std. β ΔR²
-0.139 0.10
-0.485*** 0.21
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4.4. Discussion 
The TVA-based parametric assessment of visual processing capacity, comprising four distinct 
components, revealed evidence of widespread changes in patients with MS, both at an early 
and at a later disease stage. There was a differential pattern of impairment at the two 
different disease stages assessed. Even at an early stage (EMS), where CI as assessed by 
conventional neuropsychological testing was the exception, patients showed significant 
modifications in 3 of the 4 TVA parameters: i.e. iconic memory, VSTM storage capacity, and 
processing rate. The later stage (LMS) was characterized by a quantitative increase of 
parameter deviations, as well as by a qualitative change, i.e. the emergence of an elevated 
perceptual threshold. The threshold values had a significant relationship to disease 
progression in general and to impaired information-processing speed and visual memory 
functioning in particular. 
The results of the present study are in line with the evidence that visual dysfunction is one of 
the most common clinical manifestations of multiple sclerosis (Sakai, Feller, Galetta, Galetta, 
& Balcer, 2011), and CI in MS is particularly prevalent in tasks involving visual processing 
(Kavcic & Scheid, 2011; Laatu, Revonsuo, Hämäläinen, Ojanen, & Ruutiainen, 2001; Lopes 
Costa et al., 2016; Moster, Wilson, Galetta, & Balcer, 2014; Utz et al., 2013). Accordingly, 
performance in our TVA-based whole report task could, in principle, be affected by damage 
at each level of the visual hierarchy, from the retina to higher order brain areas involved in 
attention functions. We would, however, suggest that elementary sensory deficits have a 
minor role, only, in accounting for our results, for the following reasons: Firstly, individual 
adjustment of exposure durations compensated for differences in sensory functions. 
Secondly, patients with and without a history of optic neuritis did not differ significantly with 
respect to any of the TVA-based parameter estimates. Nevertheless, as we did not include a 
direct measure of basic visual functions, like e.g. low-contrast letter acuity, an influence of 
basic sensory differences on our results cannot be completely ruled out. Note, however, that 
impairment of visual contrast sensitivity may, on the other hand, actually be an effective 
marker of post-geniculate white matter pathology in MS (Wu et al., 2007).  
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Recently, Fielding et al. (2015) have suggested that using behavioral tasks assessing 
oculomotor functions can tell a lot about the integrity of brain networks that form the 
scaffolding of cognition. In a similar vein, we would suggest that TVA-based assessment may 
also represent a sensitive index for the disruption of the brain networks underlying 
cognition. The visual perception and attention system is intimately connected with nodes of 
higher order brain networks underlying cognitive functions, with a large part of the cerebral 
cortex being responsive to visual input (Felleman & Van Essen, 1991). Therefore, measuring 
the efficiency of visual information uptake may provide a means for sensitively detecting 
network derangements. The possibility to validly map the integrity of neuro-cognitive 
networks may also be the reason why extracting information from rapid visual displays has 
long been known to be a good predictor of intellectual ability (see Deary et al., 2001). 
According to this view, there would be no causal relationship between the parameters of 
visual information uptake, as provided by TVA, and cognitive functions. Instead, much like 
measuring body temperature as a global index of the activity of an infectious disease, 
assessing visual processing capacity may provide important information about different 
aspects of cerebral network functionality. For example, in a TVA-based study in normal 
subjects, individual differences in parameters K and C were found to be directly linked to 
structural differences within the long-association fronto-parietal white matter pathways 
(Chechlacz, Gillebert, Vangkilde, Petersen, & Humphreys, 2015). Similarly, in an earlier TVA-
based study in patients with mild cognitive impairment and early Alzheimer’s disease (AD) 
(Bublak et al., 2011), declines of  VSTM storage capacity and processing rate as revealed at 
the stage of manifest dementia, were interpreted as indicating a disturbance of white matter 
connectivity appearing at later AD stages. On the other hand, an elevation of the perceptual 
threshold observed at the MCI stage, already, was suggested to reflect primary cortical 
pathology at this early stage of AD.  
The results of the present study are complementary, with processing rate and VSTM storage 
capacity changed already in early MS patients, while perceptual threshold being increased in 
the group of subjects with late MS, only. Applying a similar rationale as described above in 
the case of AD, this result could mean primary affliction of white matter connectivity by MS-
related brain pathology at an early stage, but additional cortical involvement at later stages. 
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However, such conclusions are clearly speculative and would need to be confirmed by MRI 
data using measures of lesion load and brain atrophy in combination with TVA-based 
assessment.  
The TVA-based method appears to be well-suited for that purpose. Within the tri-factor 
model of processing speed introduced by Costa et al. (2017), TVA models one specific 
aspect, i.e. sensory speed within the visual modality, and it does so with reference to an 
explicit theoretical and mathematically formalized framework. It deconstructs sensory speed 
into distinct components reflecting both velocity and maintenance aspects of visual 
processing capacity. Moreover, these components appear to be differentially affected at 
different disease stages, which allows to generate testable hypotheses about the nature and 
the underlying pathology of different parameter patterns. 
In summary, two important conclusions may be drawn from the present study. First, TVA-
based assessment may be able to identify a reduction of processing efficiency even at an 
early disease stage, when conventional neuropsychological testing is still “silent”. Second, at 
a later stage, a single procedure may be able to provide a valid status description about 
cognitive functioning in general. Therefore, TVA-based assessment may bear great potential 
for cognitive assessment in MS-patients, in particular, for early identification of patients with 
an increased risk for cognitive decline. This may enhance the chance for early intervention, 
for which recent studies have already revealed promising approaches (Huiskamp, 
Dobryakova, Wylie, DeLuca, & Chiaravalloti, 2016). 
Future directions for TVA-based investigations in MS patients may aim at underpinning 
parameter changes with MS-related brain pathology as derived from structural imaging data, 
controlling for the influence of clinical variables in a more representative patient sample, 
and collecting longitudinal data to prove the potential of TVA-based assessment as a valid 
tool for detecting imminent cognitive decline prior to its manifestation in conventional 
neuropsychological testing. 
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5. General Discussion 
The aim of this thesis was to evaluate established and novel neuropsychological assessment 
strategies for cognitive impairment in MS. For this purpose, two carefully matched groups of 
patients were recruited, one at a very early disease stage and one at a late stage. Key 
domains of MS-related cognitive impairment were assessed by using traditional 
neuropsychological tests with a particular focus on memory functioning. Additionally, a 
novel, parametric approach for modeling visual information uptake based on a theory of 
visual attention (TVA) was used to assess four distinct components of visual processing 
capacity. In three studies, the acquired data was used to evaluate (1) the comparability of 
common classification criteria of cognitive impairment, (2) associations between memory 
performance, information-processing speed and structural MRI, and (3) the extent of TVA-
based visual processing capacity decline in early versus late MS and its association with 
cognitive impairment and other disease-related variables. 
For the first study, which focused on the definition of cognitive impairment, a systematic 
review of 179 original studies was conducted to provide an overview of the different criteria 
that are used to classify impairment and to evaluate whether criterion selection might be 
influenced by disease duration and other sample characteristics. Additionally, 75 healthy 
control subjects, individually matched to the MS patients, were recruited and analogously 
cognitively assessed to provide an adequate reference for false positive classification in the 
original data. Cognitive data of patients and controls was then used to evaluate the 
classification resulting from the most commonly used criteria. 
The main implication from the first study was that classification criteria need to be better 
homogenized in respect to classification stringency. It was shown that a range of criteria are 
in use which can result in very different rates of cognitive impairment if the probability for 
false-positives is not matched. In turn, the study also demonstrated that if this probability is 
matched, it is of less relevance which exact neuropsychological tests are utilized and 
whether the classification is based on regression-based or manual-based norms, on 
impairment in specific domains or a composite score, or on a 1, 1.5, or 2 SD cut-off. 
However, the study clearly revealed that criteria selection has in fact been biased, i.e., liberal 
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criteria were more often applied in studies that evaluated patients with shorter disease 
durations. Moreover, it was suggested by the original data that in early MS only subtle signs 
of cognitive dysfunction become evident when compared to an adequate control group and 
it was therefore concluded that the significance of cognitive impairment in early MS might 
have been overestimated compared to later MS stages. It was therefore recommended that 
a more homogenized use of impairment classification should include a differentiation into 
mild, moderate and severe forms.  
In the second study, MRI was applied to patients in both groups in order to derive estimates 
of MS-related neurodegeneration in a memory-specific region, i.e., the hippocampus, and in 
the white and grey matter. This data was used in a thorough neuropsychological evaluation 
of memory impairment in MS. The focus of this study was on methodological aspects that 
were not accounted for in previous studies of memory functioning in MS and that might 
explain past inconsistencies in respect to the presence of early memory impairment and 
correlations to hippocampal atrophy. For that reason, memory assessment went beyond 
standard word list and visuospatial learning and comprised three additional validated tests 
that were not a part of standard assessment batteries for MS (see chapter 1.2.3). Also, a 
potential mediating role of the most significant cognitive deficit in MS, i.e., slowed 
information-processing speed was accounted for and finally, effects of early and late MS on 
memory functioning were evaluated separately. 
The study confirmed that there are subgroups of early MS patients that show no signs of 
meaningful memory impairment, even if they are comprehensively assessed. From these 
findings it was concluded that assessment differences may not be the reason for the 
discrepancy between studies that found early memory impairment and those that did not. It 
was speculated that subgroups can be well-preserved because of particular sample 
characteristics including younger age, shorter infraclinical course, higher proportion of 
females, advanced education, absence of depression and fatigue. The study also supported 
the notion that memory deficits in later stages are characterized by a rather global pattern 
and that this can be detected by different neuropsychological tests of episodic memory. The 
most important result of this study, however, was on the role of information-processing 
speed deficits. It was suggested by the presented data that on one hand, slowed 
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information-processing impacts memory performance in MS, and, on the other hand, is 
associated with atrophy across several memory-specific and unspecific brain regions. Thus, a 
considerable part of memory deficits in MS could be related to mental slowing that arises 
from accumulated tissue loss in later disease stages. Based on the latter findings, it was 
concluded that information-processing speed should be accounted for in future studies of 
MI in MS as a potential mediator or covariate.  
The objective of the third study was to evaluate a novel, neuropsychological assessment 
strategy based on a theory of visual attention (TVA) at early and late MS stages. The 
innovative quality of TVA-based testing is that cognitive functions are not directly assessed 
by test performance itself as in traditional neuropsychological tests. Instead, performance is 
used to model visual attention as a mathematical function according to the equations 
provided by TVA. Characteristics of the resulting curve (such as its origin, slope, and 
asymptote) are then derived to quantify distinct components that constitute the capacity of 
selective visual attention. TVA-based testing is cognitively specific, reliable and sensitive to 
minor deficits. In the present study, an experimental software solution for TVA-based testing 
was introduced to clinical neuropsychologists at five German MS centers for the assessment 
of 75 patients and the obtained parameter estimates of visual processing were compared to 
reference values of healthy adults, indicators of MS-related disease progression and 
cognitive functioning. 
A first conclusion from this study was that early visual processing deficits can be detected by 
using TVA-based testing at stages with well-preserved cognitive functioning. A second 
conclusion was that in later disease stages a different TVA-based deficit pattern emerges 
that is characterized by additional elevations of the perceptual threshold. A third conclusion 
was that the elevation of the perceptual threshold is indicative of cognitive impairment and 
disease progression. Although the study was not designed to elucidate whether the early 
deficits reflect cerebral pathology or sensorimotor damage, the existing literature of clinical 
TVA-based studies was reinterpreted in support of the former. More specifically, it was 
speculated that early visual processing deficits can be attributed to early white matter 
pathology and the later qualitative changes to additional cortical pathology. In future 
imaging studies TVA-based assessment might be applied to better understand the 
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underlying mechanism of cognitive impairment in MS. It was additionally discussed how an 
elevated perceptual threshold could explain previous findings of visual processing deficits in 
MS to support the notion of this parameter being a key determinant of visual processing 
deficits in later disease stages. Considering the fact that this was the first study to 
systematically assess TVA-based visual processing capacity at different disease stages, it was 
speculated that at early stages, TVA-based testing could have prognostic value for disease 
progression and cognitive decline; and at later stages, provide a marker of cognitive 
functioning in general. The study also showed that TVA-based testing is practicable for the 
evaluation of patients with varying levels of physical disabilities. 
The most important limitation of all three studies was the sample size of the early MS group. 
On one hand, this limits the degree to which the results can be generalized; on the other 
hand, it makes it difficult to directly compare the results with the double the size late MS 
group. It is likely that in a larger, heterogeneous sample of early stage patients, cognitive 
impairment becomes more prevalent (Ruano et al., 2017). In contrast, the present sample of 
early MS included mostly well-preserved patients. Therefore, it would be very informative to 
replicate the present investigation in a larger group of patients with early MS and probable 
cognitive impairment. 
The absence of a measured ecological validity is another limitation of the present evaluation. 
While cognitive impairment associated with stroke, Alzheimer’s disease, or traumatic brain 
injury oftentimes has high face validity in respect to day-to-day living activities, this is not the 
case for mild cognitive impairment associated with MS. Also, MS patients’ subjective 
complaints on cognitive functioning seem to reflect depression, anxiety, fatigue, and physical 
disability rather than objective indicators of cognitive impairment (Benedict et al., 2003; 
Hulst et al., 2014; Middleton, Denney, Lynch, & Parmenter, 2006). Thus, the clinical 
meaningfulness of different levels of cognitive impairment remains unclear. With respect to 
TVA-based assessment, Kluckow et al. (2016) have recently revealed an association between 
a decreased processing rate and objective fatigue. However, other promising approaches to 
link statistical significance in cognitive tests to meaningful levels of functional impairment 
have been introduced (Benedict et al., 2016) and therefore, future evaluations of 
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neuropsychological assessment strategies should include such measures of clinical 
meaningfulness. 
One more important aspect that was not accounted for in this thesis is a longitudinal 
neuropsychological evaluation (Walker et al., 2011). First, patients evaluated in the present 
thesis might have been tested prior to study inclusion, especially the four who were under 
natalizumab treatment (DGNLL, 2014; Kunkel et al., 2015; Prosperini et al., 2016), which 
could have improved their performance due to practice effects (Jønsson et al., 2006). 
Second, it is an important task to identify reliable and valid neuropsychological tests for 
multiple testing and monitoring of disease progression and cognitive deterioration 
(Hoffmann et al., 2007). For example, cognitive monitoring is explicitly recommended for the 
duration of natalizumab treatment to alert clinicians of a possible Progressive Multifocal 
Leukoencephalopathy, a serious adverse event with a 24 % mortality rate (DGNLL, 2014). 
Therefore, it is an objective for future studies to evaluate the stability and sensitivity to the 
change of traditional and TVA-based assessment in different groups of MS patients. First 
insights might be provided by a longitudinal study that was conducted by our research group 
and that included the same groups evaluated as part of this thesis. 
In conclusion, the present findings demonstrated that classification of cognitive impairment 
in MS is not fully comparable across different published criteria and needs to be better 
homogenized in respect to classification stringency. The findings also suggest that deficits in 
the speed of information processing have to be accounted for when evaluating memory 
functioning in MS patients because speed deficits affect memory. Finally, it was confirmed 
that a novel, TVA-based assessment strategy can be used to detect visual processing capacity 
decline at a stage when traditional cognitive assessment is still “silent” and in later stages 
may provide a valid estimate of cognitive functioning and disease progression. 
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Table e1. Reviewed studies for classification criteria of cognitive impairment in Multiple Sclerosis 
Publication Strategy
1
 
Number of 
relevant 
parameters
2
 
Critical 
number of 
abnormal 
Parameters 
SD 
Cut-
off 
Stringency
3
 Criteria specifics Test battery
4
 N 
Disease 
Course
5
 
Age Disease duration 
% CI
6
 
 mean SD mean SD 
(Achiron & 
Barak, 
2003) 
1 6 1 1.00 liberal 
 
BRB-N + CDT 67 CIS, MS 32.3 10.3 0.1 0.1 94.00 
(Achiron et 
al., 2013) 
2 65 N/A (1.00) N/A 
Composite score (average of 
normalized parameters) < -1 SD 
GAB 1500 MS 40.5 
SE: 
0.3 
9.7 
SE: 
0.2 
27.68 
(Amato et 
al., 2012) 
1 10 2 1.68 fair 
 
BRB-N + 
Stroop 
55 RR, RIS 35.8 8.5 8.7 7.1 30.9 
(Amato et 
al., 2004) 
1 7 1 2.00 cons. 
 
BRB-N 41 RR 35.1 8.6 4.0 2.8 56.10 
(Amato et 
al., 2001) 
1 12 3 1.68 cons. 
 
nonstandard 45 
RR, SP, 
PP 
39.1 8.3 11.3 2.3 56.00 
(Amato et 
al., 2006) 
1 10 3 1.68 cons. 
 
BRB-N + 
Stroop 
163 bMS 44.5 7.7 20.8 5.3 49.00 
(Amato, 
Portaccio, 
Goretti, 
Zipoli, 
Iudice, et 
al., 2010) 
1 10 2 1.50 fair 
 
BRB-N + 
Stroop 
49 RR 36.9 8.9 2.9 1.7 31.00 
(Batista et 
al., 2012) 
3 10 (2) 1.5; 2 N/A 
1) mean z score <-1.5 across 6 
parameters of SDMT, PASAT, 
BVMT, and CVLT; or 2) 1 
parameter >2SD and 2 parameters 
>1.5SD, or 2 Parameter >2SD  
across all 10 cognitive measures. 
MACFIMS 58 MS 43.5 6.5 9.6 6.6 48.20 
(Baumstarc
k-Barrau et 
al., 2011) 
1 8 3 2.00 cons. 
 
BRB-N 124 
CIS, RR, 
SP, PP 
45.1 10.8 
Median: 
9.9 
Range: 
0-31 
37.00 
(Benedict, 
Bruce, et 
al., 2006) 
1 6 (2) 1.5; 2 N/A 
1) 1 parameter ≥2SD and another 
≥1.5 SD; or 2) 3 parameters  ≥1.5 
SD 
nonstandard 82 RR, SP 44.6 8.5 12.2 8.2 59.80 
(Benedict, 
Cookfair, et 
al., 2006) 
1 11 2 1.50 fair 
 
MACFIMS 291 
RR, SP, 
PR, PP 
45.4 8.9 N/A N/A 59.50 
(Benedict et 
al., 2004) 
3 10 (2) 1.5; 2 N/A 
1) mean z score <-1.5 across 6 
parameters of SDMT, PASAT, 
BVMT, and CVLT; or 2) 1 
parameter >2SD and 2 parameters 
>1.5SD, or 2 Parameter >2SD  
across all 10 cognitive measures. 
MACFIMS + 
WCST 
85 MS 42.4 9.3 N/A N/A 35.00 
(Benedict et 
al., 2003) 
2 6 N/A (1.50) N/A 
Composite score (average of 
normalized parameters) < -1.5 SD 
nonstandard 50 RR, SP 42.6 7.2 10.1 6.6 24.00 
(Bester et 
al., 2013) 
1 6 2 1.60 cons. 
 
nonstandard 26 bMS 53.4 7.1 25.8 9.6 38.00 
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Table e1. Reviewed studies for classification criteria of cognitive impairment in Multiple Sclerosis 
Publication Strategy
1
 Number of 
relevant 
parameters
2
 
Critical 
number of 
abnormal 
Parameters 
SD 
Cut-
off 
Stringency
3
 Criteria specifics Test battery
4
 N Disease 
Course
5
 
Age Disease duration % CI
6
 
 (Borghi et 
al., 2013) 
1 9 2 1.50 cons. 
 
BRB-N 303 
RR, PP,
SP, RP 
43.1 10.8 10.9 7.3 35.60 
(M. 
Calabrese 
et al., 2009) 
1 8 1 2.00 cons. 
 
BRB-N 70 RR 34.8 
Range: 
18-55 
8.4 
Range: 
1-18 
34.30 
(M. 
Calabrese 
et al., 2010) 
1 7 1 2.00 cons. 
 
BRB-N 100 RR 32.2 7.2 6.2 2.6 39.00 
(Camp et 
al., 2005) 
1 9 3 2.00 cons. 
 
BRB-N 99 PP 48.6 9.7 10.4 7.0 21.21 
(Camp et 
al., 1999) 
1 11 3 2.00 cons. 
 
BRB-N + 
VESPAR 
63 PP, TP 47.7 9.9 11.6 7.1 28.60 
(Correale et 
al., 2012) 
1 6 3 2.00 cons. 
 
nonstandard 43 bMS 37.2 7.1 10.8 0.6 47.00 
(Deloire et 
al., 2005) 
1 15 (2) 1.68 N/A 
2 out of 10 tests abnormal (i.e. min. 
1 parameter of each test abnormal) 
BRB-N + 
nonstandard 
58 RR 37.3 9.2 2.0 2.2 44.80 
(Deloire et 
al., 2010) 
1 12 2 1.68 fair 
 
BRB-N + 
nonstandard 
46 RR 38.6 8.7 2.0 2.3 47.80 
(Deloire et 
al., 2006) 
1 15 (2) 1.68 N/A 
2 out of 10 tests abnormal (i.e. min. 
1 parameter of each test abnormal) 
BRB-N + 
nonstandard 
57 RR 37.2 9.2 2.1 2.2 59.70 
(Denney et 
al., 2008) 
2 12 N/A (0.5; 1) N/A 
Composite score (average of 
normalized parameters) < 0.5 SD 
and 1 out of 3 cognitive factor 
scores (based on factor analysis) > 
1 SD 
nonstandard 24 PP 50.3 
Range: 
30-63 
5.4 
Range: 
1-21 
37.50 
(Dusankova
, Kalincik, 
Havrdova, 
& Benedict, 
2012) 
1 10 2 1.50 fair 
 
MACFIMS 369 
RR, SP, 
PP, RP 
34.0 10.0 8.0 7.0 55.00 
(Faiss et 
al., 2014) 
1 18 1 2.00 liberal 
 
nonstandard 47 CIS 31.2 8.9 0.1 0.1 55.30 
(Feinstein, 
Lapshin, 
O’Connor, 
& Lanctôt, 
2013) 
1 6 2 1.50 cons. 
 
MACFIMS 144 
RR, SP, 
PP 
46.8 8.6 11.5 10.3 31.90 
(Feuillet et 
al., 2007) 
1 20 2 2.00 cons. 
 
BRB-N + 
nonstandard 
40 CIS 30.9 6.7 2.8 0.5 57.00 
(Glanz et 
al., 2007) 
1 8 1 1.50 liberal 
 
BRB-N 92 CIS, MS 36.5 8.7 0.8 0.9 49.00 
(Glanz et 
al., 2010) 
1 8 1 1.50 liberal 
 
BRB-N 92 CIS, RR 36.5 8.7 0.8 0.9 46.00 
(Goretti et 
al., 2010) 
1 10 2 2.00 cons. 
 
BRB-N + 
Stroop 
63 RR,SP 42.6 10.1 14.7 10.8 36.50 
(Hulst et al., 
2013) 
1 5 2 2.00 cons. 
 
nonstandard 55 RR, SP 48.0 7.1 11.7 7.0 36.40 
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Table e1. Reviewed studies for classification criteria of cognitive impairment in Multiple Sclerosis 
Publication Strategy
1
 Number of 
relevant 
parameters
2
 
Critical 
number of 
abnormal 
Parameters 
SD 
Cut-
off 
Stringency
3
 Criteria specifics Test battery
4
 N Disease 
Course
5
 
Age Disease duration % CI
6
 
 (Inglese et 
al., 2008) 
1 10 2 1.68 fair 
 
nonstandard 32 RR, PP 51.1 
Range: 
29-71 
6.5 
Range: 
1-34 
56.30 
(Jønsson et 
al., 2006) 
2 30 N/A (1.50) N/A 
2 out of 7 cognitive domain scores 
(average  of associated normalized 
parameters) < -1.5 SD 
nonstandard 80 
RR, PP, 
SP 
35.0 
Range: 
20-59 
0.6 
Range: 
0.1-2 
43.70 
(Jønsson et 
al., 2006) 
1 30 5 1.50 fair 
 
nonstandard 80 
RR, PP, 
SP 
35.0 
Range: 
20-59 
0.6 
Range:  
0.1-2 
47.50 
(Khalil et 
al., 2011) 
2 9 N/A (1.68) N/A 
1 out of 4 cognitive domain scores 
(average of associated normalized 
parameters) < -1.68 
BRB-N 44 CIS 33.9 10.0 
Median: 
0.2 
N/A 18.20 
(Lapshin, 
Lanctôt, 
O’Connor, 
& Feinstein, 
2013) 
1 10 2 1.50 fair 
 
MACFIMS 96 
RR, SP, 
PP 
48.5 9.8 11.3 8.5 41.70 
(Lazeron et 
al., 2005) 
3 6 (2) (2.00) N/A 
1) composite score (sum of 
normalized parameters < -0.33 
SD); or 2) two or more parameters 
below 2 SD 
BRB-N 82 
RR, SP, 
PP 
47.0 
Range: 
27-73 
10.5 
Range: 
1-27 
67.00 
(Leone et 
al., 2013) 
1 9 3 1.68 cons. 
 
BRB-N + 
Stroop 
61 
CIS, RR, 
SP, PP 
43.9 11.8 13.3 9.5 47.50 
(Marrie, 
Chelune, 
Miller, & 
Cohen, 
2005) 
1 7 1 1.68 fair 
 
WAIS-III, 
WMS-III 
136 
RR, SP, 
PP 
45.4 8.7 N/A N/A 56.00 
(Marrie, 
Miller, 
Chelune, & 
Cohen, 
2003) 
1 7 1 1.68 fair 
 
WAIS-III, 
WMS-III 
136 
RR, SP, 
PP 
42.4 13.7 7.1 10.0 56.00 
(Mathiesen 
et al., 2006) 
2 29 N/A (1.50) N/A 
1.5 SD cut-off on composite score 
(sum of those normalized 
parameters that highly 
intercorrelate [Cronbach alpha=.76] 
and have a mean below T=50) 
nonstandard 20 RR 36.0 8.0 <5 N/A 45.00 
(Mesaros et 
al., 2009) 
1 13 3 2.00 cons. 
 
nonstandard 54 bMS 46.4 
Range: 
35-63 
22.5 
Range: 
15-39 
17.00 
(Mesaros et 
al., 2012) 
1 8 (2) 1.5; 2 N/A 
1) 1 parameter ≥2SD and another 
≥1.5 SD; or 2) 3 parameters  ≥1.5 
SD 
BRB-N 82 
RR, SP, 
PP, bMS 
44.0 
Range: 
22-60 
12.1 
Range: 
1-40 
40.20 
(Nocentini 
et al., 2006) 
1 8 2 1.65 cons. 
 
MDB 461 RR 35.9 8.4 
Median: 
6.3 
N/A 31.00 
(Nocentini 
et al., 2014) 
1 13 2 1.68 fair 
 
nonstandard 18 RR, SP 41.4 9.8 15.0 7.0 55.56 
(Parmenter 
& 
1 10 2 1.50 fair 
 
MACFIMS w/o 
SDMT 
100 RR, SP 44.6 8.4 N/A N/A 55.00 
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Table e1. Reviewed studies for classification criteria of cognitive impairment in Multiple Sclerosis 
Publication Strategy
1
 Number of 
relevant 
parameters
2
 
Critical 
number of 
abnormal 
Parameters 
SD 
Cut-
off 
Stringency
3
 Criteria specifics Test battery
4
 N Disease 
Course
5
 
Age Disease duration % CI
6
 
 Weinstock-
Guttman, 
2007) 
(Patti et al., 
2009) 
1 10 3 1.00 fair 
 
BRB-N + 
Stroop 
550 RR 33.4 8.3 5.0 5.3 22.00 
(Penny et 
al., 2013) 
1 13 2 1.68 fair 
 
nonstandard 61 
CIS, RR, 
SP 
40.4 
Range: 
25-57 
6.9 
Range: 
5-10 
29.80 
(Penny, 
Khaleeli, 
Cipolotti, 
Thompson, 
& Ron, 
2010) 
1 12 3 2.00 cons. 
 
nonstandard 31 PP 51.0 
Range: 
11-18 
8.9 
Range:  
7-12 
29.00 
(Portaccio 
et al., 2006) 
1 9 1 2.00 cons. 
 
BRB-N 41 RR 35.1 8.6 4.0 2.8 56.10 
(Portaccio 
et al., 2009) 
1 10 2 2.00 cons. 
 
BRB-N + 
Stroop 
85 RR 43.0 8.4 15.8 9.6 33.00 
(Potagas et 
al., 2008) 
1 9 3 1.68 cons. 
 
BRB-N 160 MS 38.5 9.0 6.8 4.9 52.80 
(Riccitelli et 
al., 2011) 
1 7 2 2.00 cons. 
 
nonstandard 73 
RR, SP, 
PP 
42.7 
Range: 
22-63 
11.2 
Range: 
1-39 
53.00 
(Rocca et 
al., 2010) 
1 11 3 2.00 cons. 
 
nonstandard 16 PP 49.7 
Range: 
39-68 
10.0 
Range: 
4-21 
37.00 
(Rossi et 
al., 2012) 
1 8 2 2.00 cons. 
 
BRB-N 142 RR 39.4 9.1 11.0 9.8 25.35 
(Rosti, 
Hämäläinen
, Koivisto, & 
Hokkanen, 
2007) 
1 34 7 1.68 cons. 
 
nonstandard 45 RR 42.7 8.3 N/A N/A 42.22 
(Rovaris et 
al., 2002) 
1 10 (3) 2.00 N/A 
Abnormal parameters in at least 
two out of five different cognitive 
domains 
nonstandard 34 RR 34.8 7.5 6.5 
Range: 
1-20 
26.50 
(Ruet et al., 
2013) 
1 10 2 1.50 fair 
 
BRB-N + SR 65 RR 39.0 10.4 2.6 3.2 52.30 
(Sánchez et 
al., 2008) 
2 22 N/A (1.68) N/A 
5th percentile cut-off on composite 
score (grading system for each 
parameter: 1-2 SD below normative 
mean [=1], more than 2 SD [=2]) 
nonstandard 52 RR 31.7 8.4 2.9 2.5 40.00 
(Sayao, 
Bueno, 
Devonshire, 
& Tremlett, 
2011) 
1 5 2 1.68 cons. 
 
NSBMS 47 bMS 27.7 7.4 27.2 1.8 17.00 
(Simioni et 
al., 2007) 
1 13 1 2.00 fair 
 
nonstandard 106 CIS, MS 34.1 9.3 2.6 1.8 29.30 
(Smestad et 1 15 (2) 1.50 N/A Abnormal parameters in at least nonstandard 84 MS 61.8 Range: 34.5 Range: 48.00 
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Table e1. Reviewed studies for classification criteria of cognitive impairment in Multiple Sclerosis 
Publication Strategy
1
 Number of 
relevant 
parameters
2
 
Critical 
number of 
abnormal 
Parameters 
SD 
Cut-
off 
Stringency
3
 Criteria specifics Test battery
4
 N Disease 
Course
5
 
Age Disease duration % CI
6
 
 al., 2010) two of the four main functional 
areas (psychomotor speed, 
attention, memory, executive) 
45-84 27-62 
(Till et al., 
2011) 
1 16 3 1.50 fair 
 
nonstandard 35 MS 16.4 2.4 4.3 3.1 29.40 
(Weinges-
Evers et al., 
2010) 
2 10 N/A (1.68) N/A 
Composite score (average of 
normalized parameters) < -1.68 SD 
BRB-N + FST 109 RR 39.3 8.8 2.9 2.4 5.50 
(Younes et 
al., 2007) 
1 18 1 2.05 liberal 
 
nonstandard 40 
RR, SP, 
RP, PP 
45.0 10.2 10.0 7.4 46.00 
(Zipoli et 
al., 2010) 
1 10 2 2.00 cons. 
 
BRB-N + 
Stroop 
56 CIS 33.2 8.5 0.0 0.0 25.00 
(Zipoli et 
al., 2010) 
1 10 3 2.00 cons. 
 
BRB-N + 
Stroop 
56 CIS 33.2 8.5 0.0 0.0 14.00 
(Zivadinov, 
De Masi, et 
al., 2001) 
1 18 (2) 2.00 N/A 
Abnormal parameters in at least 
two out of six different cognitive 
domains 
nonstandard 63 RR 35.4 9.1 5.8 3.3 23.80 
(Zivadinov, 
Sepcic, et 
al., 2001) 
1 18 (2) 2.00 N/A 
Abnormal parameters in at least 
two out of six different cognitive 
domains 
nonstandard 53 RR 30.2 9.4 3.8 1.3 26.40 
1: Classification can be based on (1) the number of abnormal test parameters, (2) on the formation of a composite index, or (3) on a combination of the first two. 
2: The number of cognitive parameters on which the classification criteria have been applied on 
3: When possible the criteria were classified in respect of their stringency (liberal, fair, or conservative). This was based on false positive rates, i.e., on how many parameters healthy people fail on a cut-off of 1, 1.5, and 2 
SD(Schretlen et al., 2008). Criteria were considered fair if CI was defined as performance below 1 SD on 32%±6.4%, on less than 25.6% as liberal, and on more than 38.4% as conservative. The respective figures were 
17±3.4% for the 1.5 SD / 5th percentile cut-off, and 7.5±1.5% for the 2 SD cut-off. 
4: BRB-N = Brief Repeatable Battery of Neuropsychological Tests; CDT = Clock Drawing Test; FST = Faces Symbol Test; GAB = MindStreams Global Assessment Battery; MACFIMS = The Minimal Assessment of 
Cognitive Function in Multiple Sclerosis;  MDB = Mental deterioration battery; NSBMS = Rao’s Neuropsychological Screening Battery for MS; RIS=radiologically isolated syndrome; SDMT = Symbol Digit Modalities Test; SR 
= similarities subtest of the WAIS; Stroop = Stroop Test; VESPAR = Verbal and Spatial Reasoning Test; WAIS-III=Wechsler Adult Intelligence Scale, Third Edition; WCST = Wisconsin Card Sorting Test; WMS-III = 
Wechsler Memory Scale, Third Edition 
5: RP=Relapsing Progressive PP=Primary Progressive MS; TP= Transitional Progressive MS; SP=Secondary Progressive MS; RR=Relapsing Remitting; CIS=Clinically isolated syndrome 
6: Percentage of cognitive impairment 
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Deutsche Zusammenfassung 
Ziel der vorliegenden Dissertation war die Untersuchung etablierter und neuartiger 
Testverfahren zur Erfassung neurokognitiver Störungen bei Patienten mit Multiple Sklerose 
(MS). In drei Studien wurden folgende Fragestellungen beantwortet: (1): Welche Kriterien 
existieren für die Klassifikation einer kognitiven Störung bei MS und wie zuverlässig sind die 
daraus folgenden Ergebnisse in verschiedenen Krankheitsstadien? (2): Welche 
Gedächtnisstörungen lassen sich durch die Verwendung multipler Gedächtnistests und nach 
Berücksichtigung einer verlangsamten Verarbeitungsgeschwindigkeit in homogenen 
Gruppen mit jeweils früher oder später MS nachweisen? (3): Lassen sich durch die 
Verwendung eines neuartigen, auf der Theorie der Visuellen Aufmerksamkeit (TVA) 
basierenden Testverfahrens Defizite der visuellen Verarbeitungsfähigkeit in der Früh- und 
Spätphase der MS ermitteln und bestehen Zusammenhänge zu Defiziten in der 
konventionellen kognitiven Testung? 
Zwei parallelisierte Gruppen mit insgesamt 77 MS Patienten wurden multizentrisch 
rekrutiert und mittels einer umfangreichen Batterie traditioneller neuropsychologischer 
Testverfahren, eines experimentellen, TVA-basierten Verfahrens (whole report) und mittels 
Magnetresonanztomographie untersucht. Erfasst wurden verschiedene Aspekte des 
verbalen und visuellen Gedächtnisses, quantitative und qualitative Aspekte der 
Informationsverarbeitungsgeschwindigkeit, visuell-konstruktive Fähigkeiten, vier TVA-
basierte Parameter der visuellen Verarbeitungsfähigkeit, sowie hippokampales Volumen, 
Gesamthirnvolumen, kortikale Dicke und T1/T2 Läsionsvolumina. Zusätzlich wurde ein 
systematisches Review über verwendete Klassifikationskriterien durchgeführt und es 
wurden zwei parallelisierte Kontrollgruppen mit insgesamt 75 Probanden auf gleiche Weise 
neuropsychologisch untersucht wie die Patienten. 
Im Rahmen des systematischen Reviews konnte gezeigt werden, dass in der Literatur 
verschiedenste Kriterien für die Definition einer kognitiven Störung bei MS Anwendung 
finden. Diese können zu beträchtlichen Klassifikationsunterschieden in Hinblick auf die 
Prävalenzrate führen. Außerdem ließ sich in der Literatur ein signifikanter Zusammenhang 
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zwischen der Schärfe des ausgewählten Kriteriums und der Erkrankungsdauer der 
untersuchten Stichprobe nachweisen.  
Reduzierte Gedächtnisleistungen fanden sich über alle eingesetzten Testverfahren hinweg in 
der Gruppe mit später MS, jedoch in keinem Test in der Gruppe mit früher MS. In der 
Spätphase fanden sich zudem Zusammenhänge zwischen Gedächtnisdefiziten und Einbußen 
in der Verarbeitungsgeschwindigkeit. Nach statistischer Kontrolle des Einflusses der 
Verarbeitungsgeschwindigkeit war ein Zusammenhang zwischen hippokampaler Atrophie 
und Defiziten im verbalen Gedächtnis nachweisbar. Defizite im visuellen Gedächtnis waren 
hingegen mit kortikaler Dicke assoziiert. 
In der kognitiv weitestgehend unbeeinträchtigten Gruppe mit früher MS ließen sich mittels 
TVA-basierter Testung Defizite der visuellen Verarbeitungsfähigkeit nachweisen. In der 
Spätphase waren die Defizite quantitativ und qualitativ stärker ausgeprägt. Die 
ausschließlich in der Spätphase auftretende Erhöhung der visuellen Wahrnehmungsschwelle 
wies darüber hinaus Zusammenhänge mit Markern der allgemeinen Krankheitsprogression, 
Defiziten des visuellen Gedächtnisses und der Informationsverarbeitungsgeschwindigkeit 
auf. 
Die Ergebnisse legen nahe, dass es durch die Verwendung unterschiedlicher 
Klassifikationskriterien zu einer Überschätzung früher kognitiver Störungen gekommen sein 
könnte. Außerdem scheinen Gedächtnisstörungen vor allem im späteren Krankheitsverlauf, 
in relativ unspezifischer Form prävalent zu werden und teilweise auf eine verlangsamte 
Verarbeitungsgeschwindigkeit zurückzuführen zu sein. Schließlich könnten sich frühe 
Anzeichen kognitiver Veränderungen mittels TVA-basierter Testung aufdecken lassen und 
die Testung im späteren Krankheitsverlauf eine grobe Abschätzung kognitiver Defizite 
ermöglichen.
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